KR101765599B1 - Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae - Google Patents
Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae Download PDFInfo
- Publication number
- KR101765599B1 KR101765599B1 KR1020100119347A KR20100119347A KR101765599B1 KR 101765599 B1 KR101765599 B1 KR 101765599B1 KR 1020100119347 A KR1020100119347 A KR 1020100119347A KR 20100119347 A KR20100119347 A KR 20100119347A KR 101765599 B1 KR101765599 B1 KR 101765599B1
- Authority
- KR
- South Korea
- Prior art keywords
- cambium
- derived
- stem cells
- ginkgo
- cmcs
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 209
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 241000196324 Embryophyta Species 0.000 title description 10
- 241000218791 Ginkgoaceae Species 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 89
- 210000004027 cell Anatomy 0.000 claims description 73
- 230000000694 effects Effects 0.000 claims description 70
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 68
- 244000194101 Ginkgo biloba Species 0.000 claims description 67
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 42
- 210000001519 tissue Anatomy 0.000 claims description 37
- 235000011201 Ginkgo Nutrition 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- 230000012010 growth Effects 0.000 claims description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000013376 functional food Nutrition 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 210000003934 vacuole Anatomy 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- 210000003470 mitochondria Anatomy 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 7
- 238000004114 suspension culture Methods 0.000 claims description 6
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 claims description 5
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 claims description 5
- 230000000877 morphologic effect Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims 10
- 239000006166 lysate Substances 0.000 abstract description 12
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 229920003045 dextran sodium sulfate Polymers 0.000 description 63
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 52
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 42
- 102000004127 Cytokines Human genes 0.000 description 34
- 108090000695 Cytokines Proteins 0.000 description 34
- 239000000523 sample Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- 229940088598 enzyme Drugs 0.000 description 27
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 25
- 230000003078 antioxidant effect Effects 0.000 description 25
- 210000002540 macrophage Anatomy 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 22
- 229930003268 Vitamin C Natural products 0.000 description 22
- 235000019154 vitamin C Nutrition 0.000 description 22
- 239000011718 vitamin C Substances 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 238000002835 absorbance Methods 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 206010009887 colitis Diseases 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 239000000469 ethanolic extract Substances 0.000 description 13
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 12
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000287 crude extract Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000016938 Catalase Human genes 0.000 description 11
- 108010053835 Catalase Proteins 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102000043136 MAP kinase family Human genes 0.000 description 10
- 108091054455 MAP kinase family Proteins 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 101150071146 COX2 gene Proteins 0.000 description 8
- 101150109636 Inos gene Proteins 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 8
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 8
- 102000004316 Oxidoreductases Human genes 0.000 description 8
- 108090000854 Oxidoreductases Proteins 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 7
- -1 CCC Chemical compound 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 101710142885 Arginine N-succinyltransferase Proteins 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 6
- 102100023105 Sialin Human genes 0.000 description 6
- 101710105284 Sialin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229930192334 Auxin Natural products 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 239000005595 Picloram Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000002363 auxin Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000032459 dedifferentiation Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 4
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000005712 elicitor Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000003617 indole-3-acetic acid Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 229910004616 Na2MoO4.2H2 O Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 description 2
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000002520 cambial effect Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012468 concentrated sample Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 2
- 229940041260 vanadyl sulfate Drugs 0.000 description 2
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JLIDBLDQVAYHNE-YKALOCIXSA-N Abscisic acid Natural products OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 238000008998 Catalase assay kit Methods 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005976 Ethephon Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000008997 Superoxide Dismutase Assay Kit Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- HLVPIMVSSMJFPS-UHFFFAOYSA-N abscisic acid beta-D-glucopyranosyl ester Natural products O1C(CO)C(O)C(O)C(O)C1OC(=O)C=C(C)C=CC1(O)C(C)=CC(=O)CC1(C)C HLVPIMVSSMJFPS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001647 brassinosteroids Chemical class 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- ADULOCGXJMPDRK-UHFFFAOYSA-N iron;sulfanylidenemolybdenum Chemical compound [Fe].[Mo]=S ADULOCGXJMPDRK-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 함유하는 항염증 조성물에 관한 것이다. 본 발명에 따른 조성물은 DDS를 이용해 궤양성 대장염을 유발시킨 마우스 모델에 대해서도 우수한 항염증 효과를 가지는 것으로 확인된바, 염증성 질환의 예방 및 치료용 조성물로서 유용하다.
The present invention relates to an anti-inflammatory composition containing cambium-derived stem cell derived from cambium, an extract thereof, a lysate thereof, and a culture thereof. The composition according to the present invention has been found to have excellent anti-inflammatory effects against a mouse model in which ulcerative colitis has been induced using DDS, and thus it is useful as a composition for the prevention and treatment of inflammatory diseases.
Description
본 발명은 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 함유하는 항염증 조성물에 관한 것이다.
The present invention relates to an anti-inflammatory composition containing cambium-derived stem cell derived from cambium, an extract thereof, a lysate thereof, and a culture thereof.
염증(inflammation)은 병원체의 침입 또는 손상된 조직 제거를 개시하기 위해 상처부위에 대해 나타나는 지역적인 반응이다. 염증의 긍정적인 역할에도 불구하고 인간질병을 위한 가장 일반적인 발병 메커니즘의 하나가 되었다. 활성화된 백혈구(monocytes) 및 대식세포에 의한 산화질소(NO)의 생성이 강력한 염증 반응을 개시하고, 세균 병원체에 대한 초기 면역반응에서 가장 중요한 부분이 된다 (Bogdan C., Nat . Immunol., 2:907, 2001).Inflammation is a local reaction to the wound site to initiate entry of pathogens or removal of injured tissue. Despite the positive role of inflammation, it has become one of the most common onset mechanisms for human disease. The production of nitric oxide (NO) by activated monocytes and macrophages initiates a potent inflammatory response and is the most important part of the initial immune response to bacterial pathogens (Bogdan C., Nat . Immunol ., 2 : 907, 2001).
염증 반응은 조직(세포)의 손상이나 외부감염원(박테리아, 곰팡이, 바이러스, 다양한 종류의 알레르기 유발물질)에 감염되었을 때 국소 혈관과 체액 중 각종 염증 매개인자 및 면역세포가 관련되어 효소 활성화, 염증매개물질 분비, 체액 침윤, 세포 이동, 조직 파괴 등 일련의 복합적인 생리적 반응과 홍반, 부종, 발열, 통증 등 외적 증상을 나타낸다. 정상인 경우 염증반응은 외부감염원을 제거하고 손상된 조직을 재생하여 생명체 기능회복작용을 하지만, 항원이 제거되지 않거나 내부물질이 원인이 되어 염증반응이 과도하거나 지속적으로 일어나면 오히려 점막손상을 촉진하고, 그 결과 일부에서는 암 발생 등의 질환을 이끈다. 따라서, 부작용 없이 과도하고 지속적인 염증 반응을 예방할 수 있는 천연 항염증제의 개발 또한 요구되었다. Inflammatory reactions are caused by various inflammatory mediators and immune cells in the local blood vessels and body fluids when they are infected with tissue (cell) damage or external infectious agents (bacteria, fungi, viruses, various kinds of allergens) It exhibits a series of complex physiological responses such as substance secretion, fluid infiltration, cell migration, and tissue destruction, and external symptoms such as erythema, edema, fever, and pain. In normal cases, the inflammatory reaction removes the external infectious agent and regenerates the damaged tissue to regenerate the organism's function. However, if the antigen is not removed or the internal substance causes the inflammatory reaction to occur excessively or continuously, Some lead to diseases such as cancer. Thus, there has also been a need for the development of natural anti-inflammatory agents that can prevent excessive and persistent inflammatory reactions without side effects.
이에 본 발명자들은 기존 항염증제의 부작용을 최소화하고, 항염증 활성이 우수한 천연물 유래 조성물을 개발하고자 예의 노력한 결과, 은행나무과 은행나무속의 은행나무의 형성층 유래 줄기세포와 그 배양액이 우수한 항염증 효과가 있다는 것을 확인하고, 본 발명을 완성하게 되었다.
Therefore, the inventors of the present invention have found that the anti-inflammatory effect of the cambium-derived stem cells of the ginkgo and Ginkgo biloba-derived stem cells and the culture medium thereof has excellent anti-inflammatory effects as a result of efforts to minimize the side effects of the existing anti-inflammatory drugs and to develop a natural- And the present invention was completed.
본 발명의 목적은 항염증 활성을 나타내는 천연물 유래 조성물을 제공하는 데 있다.
It is an object of the present invention to provide a natural-material-derived composition showing anti-inflammatory activity.
상기와 같은 목적을 달성하기 위하여, 본 발명은 은행나무과의 형성층에서 유래되고, 탈분화를 거치지 않은 선천적 미분화세포인 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 함유하는 항염증 조성물을 제공한다. In order to achieve the above object, the present invention provides a stem cell derived from cambium, which is derived from a cambium layer and has not undergone differentiation, and at least one of cambium-derived stem cells, an extract thereof, Lt; / RTI >
본 발명은 또한, 상기 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 함유하는 염증의 예방 또는 개선용 기능성식품을 제공한다.
The present invention also provides a functional food for preventing or ameliorating inflammation comprising at least one of cambium-derived stem cells, an extract thereof, a lysate thereof, and a culture thereof.
본 발명은 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 유효성분으로 함유하는 항염증 조성물을 제공하는 효과가 있다. 본 발명에 따른 조성물은 DDS를 이용해 궤양성 대장염을 유발시킨 마우스 모델에 대해서도 우수한 항염증 효과를 가지는 것으로 확인된바, 염증성 질환의 예방 및 치료용 조성물로서 유용하다.
The present invention has an effect of providing an anti-inflammatory composition containing as an active ingredient any one or more of cambium-derived stem cells, extracts thereof, lysates thereof and cultures thereof. The composition according to the present invention has been found to have excellent anti-inflammatory effects against a mouse model in which ulcerative colitis has been induced using DDS, and thus it is useful as a composition for the prevention and treatment of inflammatory diseases.
도 1은 재료식물(은행나무)의 횡단면에서 형성층을 관찰한 사진이다.
도 2는 본 발명에 따른 줄기세포의 유도 및 분리 사진으로, 2A는 줄기세포(화살표)와 사부(phloem) 세포(별표)의 극히 다른 형태를 보이는 사진이고, 2B는 줄기세포를 분리한 후 배양 3주 후의 사진이다 (스케일 바: 1 mm).
도 3은 본 발명에 따른 줄기세포(A) 및 은행나무의 수피 절편체 유도 캘러스(B)의 고체 배양 시 사진이다 (스케일 바: 0.25 mm).
도 4는 본 배양과정의 줄기세포(A) 및 은행나무의 수피 조직에서 유도한 캘러스(B)의 세포응집정도를 관찰한 현미경 사진이다 (×100, 스케일 바: 50 ㎛).
도 5는 본 발명에 따른 줄기세포(B) 및 은행나무 체세포(B)의 현미경 사진으로 좌측하단의 스케일 바는 15 ㎛이다.
도 6은 Neutral red를 이용하여 액포를 염색 후 관찰한 본 발명에 따른 줄기세포(A) 및 은행나무 수피 조직에서 유도한 캘러스(B)의 현미경 사진으로, 우측하단의 스케일 바는 25 ㎛이다.
도 7은 본 발명에 따른 줄기세포(A) 및 은행나무 수피 조직에서 유도한 캘러스(B)의 미토콘드리아를 관찰한 사진으로 좌측하단의 스케일 바는 15 ㎛이다.
도 8은 본 발명에 따른 줄기세포의 생물반응기에서의 세포 생장곡선을 나타내는 그래프이다.
도 9는 본 발명에 따른 줄기세포(stem cell) 및 은행나무 수피 조직에서 유도한 캘러스(callus)의 증식률을 나타낸 그래프이다.
도 10은 3 L 공기부양형 생물반응기(A), 20 L 공기부양형 생물반응기(B) 및 250 L 공기부양형 생물반응기(C)에서 대량배양공정(scale-up process)을 나타내는 사진이다.
도 11은 본 발명에 따른 줄기세포(stem cell) 및 은행나무 수피 조직에서 유도한 캘러스(callus)의 동결보존 후 세포생존율을 나타낸 그래프이다.
도 12는 본 발명에 따른 줄기세포의 에탄올 추출물에 대하여 컬럼 크로마토그래피를 수행하여 수득한 120개의 분획을 TLC 분석을 통하여 각 유사패턴을 가진 7개 분획을 획득한 결과이다.
도 13은 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 MTT 분석을 통하여 세포생존율을 조사한 결과 그래프이다 (** p<0.01).
도 14는 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 nitrite 농도 측정을 통해 NO 활성 억제를 확인한 그래프이다 (* p<0.05, ** p<0.01, *** p<0.001).
도 15는 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 LPS 처리에 의한 iNOS 및 COX-2 유전자 발현량을 나타낸다.
도 16은 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 LPS 처리에 의한 ERK 및 p38 MAP kinase 활성화 정도를 웨스턴 블라팅의 의해 확인한 사진이다.
도 17은 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 LPS 처리에 의한 IκB 분해와 NF-κB 활성화 정도를 웨스턴 블라팅의 의해 확인한 사진이다.
도 18은 RAW 264.7 macrophage cell line에 본 발명에 따른 줄기세포 추출물 분획 처리 후 LPS 처리에 의한 IL-6 (A)와 TNF-α의 발현 저해 효과를 확인한 그래프이다 (* p<0.05, ** p<0.01).
도 19는 Mouse 간에서의 Normal control, vitamin C 및 본 발명에 따른 줄기세포 추출물 처리 시 GSH 농도 (A), SOD 활성 (B), catalase 활성 (C), GPx 활성 (D)를 나타내는 그래프이다(* p<0.05, ** p<0.01, *** p<0.001).
도 20은 Mouse 혈액에서의 Normal control, vitamin C 및 본 발명에 따른 줄기세포 추출물 처리 시 ALT 활성 (A), ALP 활성 (B), AST 활성 (C), LDH 활성 (D)를 나타내는 그래프이다(* p<0.05).
도 21은 DDS 염증모델에서의 은행나무의 형성층 유래 줄기세포(CMCs) 투여가 장내 염증과 체중에 미치는 영향을 나타낸다.
도 22는 DDS 염증모델에서의 은행나무의 형성층 유래 줄기세포(CMCs) 투여가 대장 내 IgA 농도에 미치는 영향을 나타낸다 (* p<0.05, ** p<0.01).
도 23은 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 MLN lymphocyte 배양액에서 cytokine 농도에 미치는 영향을 나타내는 그래프이다 (* p<0.05, ** p<0.01, *** p<0.001).
도 24는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 혈액 내 IgG 와 IgA 농도에 미치는 영향을 나타내는 그래프이다 (* p<0.05).
도 25는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 splenocyte에서 cytokine 발현에 미치는 영향을 나타내는 그래프이다 (* p<0.05, ** p<0.01, *** p<0.001). Fig. 1 is a photograph of a cambium layer observed from a cross section of a material plant (ginkgo).
FIG. 2 is a photograph showing induction and isolation of stem cells according to the present invention, wherein 2A shows extremely different forms of stem cells (arrow) and phloem cells (star table) This is a
FIG. 3 is a photograph (scale bar: 0.25 mm) of a stem cell (A) according to the present invention and a solid culture of bark cut bursa-derived callus (B).
FIG. 4 is a micrograph (× 100, scale bar: 50 μm) observing the degree of cell aggregation of callus (B) derived from stem cells (A) and bark of the ginkgo in this culturing process.
FIG. 5 is a photomicrograph of stem cells (B) and gingko somatic cells (B) according to the present invention, and the scale bar at the lower left is 15 μm.
FIG. 6 is a micrograph of a stem cell (A) according to the present invention and a callus (B) derived from a ginkgo bark tissue obtained after staining a vacuole using Neutral red, and the scale bar at the lower right side is 25 μm.
FIG. 7 is a photograph showing the mitochondria of callus (B) derived from stem cell (A) and ginkgo bark tissue according to the present invention, wherein the scale bar at the lower left is 15 μm.
FIG. 8 is a graph showing cell growth curves in a bioreactor of a stem cell according to the present invention. FIG.
FIG. 9 is a graph showing the proliferation rate of callus derived from stem cells and ginkgo biloba according to the present invention.
10 is a photograph showing a scale-up process in a 3 L air floating biological reactor (A), a 20 L air floating biological reactor (B), and a 250 L air floating biological reactor (C).
11 is a graph showing cell survival rate after cryopreservation of callus derived from stem cells and ginkgo biloba according to the present invention.
FIG. 12 shows the results obtained by performing column chromatography on the ethanol extracts of stem cells according to the present invention and obtaining the seven fractions having 120 different fractions having similar patterns through TLC analysis.
FIG. 13 is a graph showing cell viability after MTT analysis of stem cell extract fraction according to the present invention in RAW 264.7 macrophage cell line (** p <0.01).
FIG. 14 is a graph showing inhibition of NO activity (* p <0.05, ** p <0.01, *** p <0.001) by measuring the nitrite concentration after treatment with the stem cell extract fraction according to the present invention in RAW 264.7 macrophage cell line .
FIG. 15 shows the amounts of iNOS and COX-2 gene expression by LPS treatment after treatment with the stem cell extract fraction according to the present invention in RAW 264.7 macrophage cell line.
16 is a photograph showing the degree of activation of ERK and p38 MAP kinase by Western blotting by LPS treatment after treatment with a stem cell extract fraction according to the present invention in RAW 264.7 macrophage cell line.
FIG. 17 is a photograph showing the degree of IκB degradation and NF-κB activation by LPS treatment after Western blotting treatment of RAW 264.7 macrophage cell line according to the present invention.
FIG. 18 is a graph showing the inhibitory effect of IL-6 (A) and TNF-α on LPS-treated stem cell extract fraction treated with RAW 264.7 macrophage cell line according to the present invention (* p <0.05, ** p ≪ 0.01).
19 is a graph showing GSH concentration (A), SOD activity (B), catalase activity (C), and GPx activity (D) in normal control, vitamin C and stem cell extract treatment according to the present invention between mice * p < 0.05, ** p < 0.01, *** p < 0.001).
20 is a graph showing ALT activity (A), ALP activity (B), AST activity (C) and LDH activity (D) in normal control, vitamin C and stem cell extract treatment according to the present invention in mouse blood * p < 0.05).
Figure 21 shows the effects of cambium on cambium-derived stem cells (CMCs) on intestinal inflammation and body weight in the DDS inflammation model.
FIG. 22 shows the effect of cambium on cambium-derived stem cells (CMCs) on the colonic IgA concentration in the DDS inflammation model (* p <0.05, ** p <0.01).
FIG. 23 is a graph showing the effect of cambium stem cell (CMCs) extract on cytokine concentration in MLN lymphocyte culture (* p <0.05, ** p <0.01, *** p <0.001).
24 is a graph showing the effect of cambium stem cells (CMCs) extracted from cambium on blood IgG and IgA concentrations (* p < 0.05).
FIG. 25 is a graph showing the effect of cambium stem cell (CMCs) extract on cytokine expression in splenocytes (* p <0.05, ** p <0.01, *** p <0.001).
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
본 발명의 상세한 설명 등에서 사용되는 주요 용어의 정의는 다음과 같다. The definitions of the main terms used in the description of the present invention and the like are as follows.
본원에서, 유관속 "형성층"은 식물의 유관속 조직(vascular tissue) 내에 위치하는 측재분열조직으로 줄기와 뿌리에 위치한다. 형성층의 활동에 의해 식물의 비대생장이 일어나며, 그 결과 11,000년 이상의 연륜을 가진 거대 식물체가 존재할 수 있게 된다. 발생학적으로 유관속 형성층은 전형성층으로부터 기원되므로 분열조직적 연속성을 유지하면서 점진적으로 분화된 동일 분열조직으로 편의상 구분될 뿐으로 (식물형태학, 이재두 외 7인 공저, 아카데미 서적, 제10장, 1993), 본 발명에 있어서 형성층은 전형성층을 포함하는 것으로 해석된다. 이러한 형성층과 전형성층은 동일한 1기 분열조직으로서, 본 발명에 있어서 형성층 및 전형성층 조직을 사용하여 동일한 효과를 얻을 것임은 자명한 사항이다.In the present application, the vascular "cambium" is a mesenchymal tissue located within the vascular tissue of a plant and located in the stem and root. The activity of the cambium causes the growth of plants, resulting in the presence of large plants with an annual ring of more than 11,000 years. The development of the anatomical structure of the anatomical structure is the same as that of the same organism (Fig. 10, 1993) In the invention, the cambium layer is interpreted to include a procambium layer. It is a matter of course that the same effect is obtained by using the cambium layer and the procambium layer structure in the present invention as the cambium and cambium layer being the same first divisional tissue.
본원에서 "파쇄물"이란 세포를 detergent 등을 이용한 화학적 방법 또는 물리적 방법 등으로 파쇄하여 얻은 세포 용해물을 의미하며, 세포주의 "추출물"이란 세포를 용매에 녹여 분리한 물질로, 증류 또는 증발을 이용하여 농축될 수 있다. 또한, 세포주 "배양액"이란 세포를 배양시킨 다음, 세포를 제외하고 남은 세포 배양용액을 의미한다. 추가적으로 본원에서 "배양물"이란 배양액 및/또는 배양된 세포주를 포함하는 물질로서, 이때 배양된 세포주는 배양조건에 의하여 분화되거나 유용물질의 생산능 및/또는 분비능이 향상된 세포주를 모두 포함하는 개념이다.As used herein, the term "lysate" means a cell lysate obtained by disrupting a cell by a chemical method or a physical method using detergent or the like. The "extract" of a cell line is a substance obtained by dissolving a cell in a solvent and using distillation or evaporation ≪ / RTI > The term "culture solution" of a cell line refers to a cell culture solution remaining after cells are cultured. In addition, the term "culture product" in the present application is a concept including a culture solution and / or a cultured cell line, wherein the cultured cell line includes all cell lines that are differentiated by culture conditions or have improved productivity and / .
본원에서 식물 "줄기세포"(stem cell)란, 탈분화 과정을 거치지 않아 유전적으로 보다 안정한 선천적인 미분화세포를 말한다. The term "stem cell " as used herein refers to a congenitally undifferentiated cell that is genetically more stable and does not undergo a process of dedifferentiation.
본원에서 "선천적인 미분화 상태(innately undifferentiated)"란 탈분화 과정을 거쳐 미분화 상태로 존재하는 것이 아닌, 본래부터 분화 전 상태를 유지하는 것을 말한다.The term " innately undifferentiated "as used herein refers to maintaining the pre-differentiation state, rather than being undifferentiated through a dedifferentiation process.
본원에서 "캘러스"란, 탈분화 과정을 통하여 분화하지 않은 상태로 된 세포 또는 세포덩어리(Proc . Natl . Acad . Sci . U. S. A., 99(25):15843, 2002)를 말한다. "Callus" herein refers to a cell or cells in non-differentiated state through a dedifferentiation process, lumps (Proc Natl Acad Sci USA, 99 (25):.... 15843, 2002) refers to.
본 발명은 일 관점에서, 은행나무과의 형성층 유래 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 함유하는 항염증 조성물에 관한 것이다.In one aspect, the present invention relates to an anti-inflammatory composition containing at least one of a cambium stem cell derived from cambium, an extract thereof, a lysate thereof, and a culture thereof.
본 발명에 따른 은행나무과의 형성층 유래 줄기세포는 은행나무과의 형성층에서 유래되고, 탈분화를 거치지 않은 선천적 미분화세포이다. 이는 다음 중 적어도 하나의 특성을 가지는 것을 특징으로 할 수 있다:The cambium-derived stem cells derived from the ginkgoaceae according to the present invention are derived from cambium-derived cambium and are undifferentiated, undifferentiated, cells. It may be characterized in that it has at least one of the following characteristics:
(a) 현탁배양 시 은행나무과의 탈분화된 캘러스에 비하여 많은 수의 단세포를 포함하거나 작은 사이즈의 세포 집합체를 포함함;(a) contains a large number of single cells or a small-sized cell aggregate as compared to the dedifferentiated callus of Ginkgo biloba during suspension culture;
(b) 다수의 액포(vacuole)를 가지는 형태학적 특징을 나타냄;(b) exhibits morphological features with multiple vacuoles;
(c) 은행나무과의 탈분화된 캘러스에 비하여 활성이 증가된 미토콘드리아를 가짐;(c) has an increased activity of mitochondria compared to dedifferentiated callus of Ginkgo biloba;
(d) 은행나무과의 탈분화된 캘러스에 비하여 생장속도가 빠르고 오랫동안 성장할 수 있음; 및(d) Growth rate is faster and longer than that of demineralized callus from ginkgo; And
(e) 은행나무과의 탈분화된 캘러스에 비하여 생물반응기에서 전단 스트레스(shear stress)에 대해 낮은 민감성을 가짐.(e) Has low sensitivity to shear stress in bioreactors as compared to demineralized callus from Ginkgo biloba.
이때, "다수의 액포"를 가진다고 함은, 은행나무과의 탈분화된 캘러스로부터 유래된 세포 등과 비교하여 2배 이상의 다수의 액포를 가짐을 말한다. 아울러, 본 발명에 따른 줄기세포는 은행나무과의 캘러스로부터 유래된 세포 등과 비교하여 크기면에서 작은 액포를 가진다. 아울러, "다수의 발달된 형태의 미토콘드리아"를 가진다고 함은, 은행나무과의 탈분화된 캘러스로부터 유래된 세포와 비교하여 광학 현미경 BX41(Olympus, Japan)하에서 활발하게 움직이는 미토콘드리아를 2배 이상의 다수 가짐을 말한다.The term "having a plurality of vacuoles " means that the cells have a plurality of vacuoles more than twice as much as those derived from a callus derived from a dedifferentiated callus. In addition, the stem cells according to the present invention have small vacuoles in size in comparison with cells derived from callus of Ginkgo biloba. In addition, "having a number of advanced forms of mitochondria" refers to a multiplicity of more than two-fold greater activity of mitochondria under an optical microscope BX41 (Olympus, Japan) as compared to cells derived from demineralized callus from ginkgo .
본 발명에 있어서, 상기 줄기세포는 상기 (a) 내지 (e)의 특성 중 적어도 2 이상의 특성을 가지는 것을 특징으로 할 수 있으며, 바람직하게는 상기 (a) 내지 (e)의 특성 중 적어도 3 이상의 특성을 가지는 것을 특징으로 할 수 있으며, 더욱 바람직하게는 상기 (a) 내지 (e)의 특성 중 적어도 4 이상의 특성을 가지는 것을 특징으로 할 수 있다. 아울러, 본 발명에 있어서, 상기 줄기세포는 (a) 내지 (e)의 특성을 모두 가지는 것을 특징으로 할 수 있다. In the present invention, the stem cells may be characterized in that they have at least two or more of the characteristics of (a) to (e), and preferably at least 3 or more of the characteristics of (a) to (e) , And more preferably at least four of the characteristics (a) to (e). In addition, in the present invention, the stem cells may be characterized by having all of the characteristics (a) to (e).
한편, 본 발명에 따른 줄기세포는 (a) 은행나무과 식물로부터 형성층 함유 조직을 수득하는 단계; (b) 상기 수득된 형성층 함유 조직을 배지에서 배양하는 단계; 및 (c) 상기 형성층으로부터 세포들을 분리함으로써 형성층 유래 줄기세포를 수득하는 단계를 포함하는 분리방법에 의하여 얻어질 수 있는데, 이때, 상기 (b) 단계는 형성층 함유 조직을 배양하여 형성층으로부터 증식되는 형성층의 층(cambium layer)을 유도하는 것을 특징으로 할 수 있고, 상기 (c) 단계는 상기 형성층의 층(cambium layer)을 분리함으로써 형성층 유래 줄기세포를 수득하는 것을 특징으로 할 수 있다. 아울러, 상기 (b)단계는 옥신(auxin)을 포함한 배지에서 배양하는 것을 특징으로 할 수 있는데, 이때, 옥신으로는 NAA (α-naphtalene acetic acid), IAA (indole-3-acetic acid) 또는 피클로람(picloram)를 사용할 수 있으며, 이러한 옥신은 1~5 ㎎/L의 농도로 포함되는 것을 특징으로 할 수 있다. 또한, 상기 (c) 단계는 형성층 이외의 부분으로부터 무정형으로 증식되는 캘러스 층으로부터 상기 형성층의 층(cambium layer)을 분리함으로써 형성층 유래 줄기세포를 수득하는 것을 특징으로 할 수 있다. On the other hand, the stem cells according to the present invention comprise (a) obtaining a cambium-containing tissue from a ginkgo plant; (b) culturing the obtained cambium-containing tissue in a medium; And (c) separating the cells from the cambium layer to obtain cambium-derived stem cells, wherein (b) comprises culturing the cambium-containing tissue to grow cambium The cambium layer of cambium-derived stem cells may be derived by separating the cambium layer from the cambium layer of step (c). In addition, the step (b) may be performed in a culture medium containing auxin, wherein the auxin is selected from the group consisting of NAA (alpha -naphthalene acetic acid), IAA (indole-3-acetic acid) Picloram may be used, and such auxin may be contained at a concentration of 1 to 5 mg / L. In the step (c), cambium layer is separated from a callus layer grown amorphously from a portion other than the cambium layer to obtain cambium-derived stem cells.
본 발명에서 상기 배양물은, 상기 줄기세포를 엘리시터로서 3~5 %(g/L)의 원당 또는 설탕; 또는 메틸 자스모네이트(methyl jasmonate), 키토산, 페닐알라닌(phenylalanin), 벤조익산, ABA, 살리실산(salicylic acid) 및 아세트산 나트륨(sodium acetate) 중 어느 하나 이상을 포함하는 배지에서 추가로 배양하는 단계를 추가로 수행하여 수득된 것임을 특징으로 할 수 있다. 이때, 바람직하게는 상기 배지는 3~5 %(g/L)의 원당 또는 설탕; 및 메틸 자스모네이트(methyl jasmonate), 진균류 추출물, 세균류 추출물, 효모(yeast) 추출물, 키토산, 글루코마난(glucomanan), 글루칸(glucan), 페닐알라닌(phenylalanine), 벤조산(benzoic acid), 살리실산(salicylic acid), 아라키돈산(arachidonic acid), STS, mevalonalonate N-benzolyglycine, ABA, SNP, IPP, BHT, CCC, 에테폰(ethephon), 히푸익산(hippuic acid), 세릭 암모니움 니트레이트(ceric ammonium nitrate), AgNO3, 바나딜 설페이트(vanadyl sulfate), p-아미노벤조익산(p-aminobenzoic acid), 브라시노스테로이드(brassinosteroids), 소디움 알지네이트(sodium alginate), 아세트산 나트륨(sodium acetate)로 구성되는 군에서 선택된 물질을 포함하는 배지임을 특징으로 할 수 있다.In the present invention, the culture may be prepared by culturing the stem cells in an amount of 3-5% (g / L) of raw sugar or sugar as an elicitor; Or further culturing in a culture medium containing at least one of methyl jasmonate, chitosan, phenylalanine, benzoic acid, ABA, salicylic acid and sodium acetate. . [0042] The above-mentioned " Preferably, the medium comprises 3-5% (g / L) of sugar or sugar; And methyl jasmonate, fungal extracts, bacterial extracts, yeast extracts, chitosan, glucomanan, glucan, phenylalanine, benzoic acid, salicylic acid ABA, SNP, IPP, BHT, CCC, ethephon, hippuic acid, ceric ammonium nitrate, and the like. material selected from the group consisting of AgNO 3, vanadyl sulfate (vanadyl sulfate), p- amino acid benzo (p -aminobenzoic acid), bra Sino steroid (brassinosteroids), sodium alginate (sodium alginate), sodium (sodium acetate) ethyl And a culture medium.
본 발명에서 또한, 상기 줄기세포에 엘리시터로서 자외선, 열, 에틸렌, 항진균제, 항생제, 중금속 염 및 높은 염농도 등을 처리하여 물리적 화학적 스트레스를 가하여 수득된 배양물을 이용할 수 있다.In the present invention, it is also possible to use a culture obtained by subjecting the stem cells to ultraviolet rays, heat, ethylene, an antifungal agent, an antibiotic, a heavy metal salt and a high salt concentration as an elicitor and applying physical and chemical stress thereto.
본 발명에 있어서 또한, 상기 추출물은 증류수, 알코올, 아세톤, DMSO (dimethyl sulfoxide) 및 이들의 혼합용매로 구성된 군에서 선택된 용매를 이용하여 추출된 것을 특징으로 할 수 있다.In the present invention, the extract may be extracted using a solvent selected from the group consisting of distilled water, alcohol, acetone, dimethyl sulfoxide (DMSO), and a mixed solvent thereof.
본 발명의 일 실시예에서는 은행나무과 은행나무속(genus Ginkgo)의 은행나무(Ginkgo biloba )로부터 은행나무의 형성층 유래 줄기세포를 분리하여 항염증 활성을 확인하였으며, 이에 본 발명은 바람직하게는 은행나무속(genus Ginkgo) 식물의 형성층 유래 줄기세포를 사용하며, 더욱 바람직하게는 은행나무의 형성층 유래 줄기세포를 사용하는 것을 특징으로 할 수 있다. In an embodiment of the present invention the Ginkgo bank Araliaceae bank hawthorn (genus Ginkgo) (Ginkgo It has confirmed that the anti-inflammatory activity by biloba) separating the cambium-derived stem cells of Ginkgo from, and thus the present invention is a preferably a bank hawthorn (genus Ginkgo) uses the cambium-derived stem cells of a plant, more preferably from Ginkgo Stem cells derived from cambium can be used.
본 발명의 실시예에서는, 본 발명에 따른 줄기세포 추출물 및 그 분획이 in vitro 뿐만 아니라 in vivo 항산화 활성 및 항염증 활성을 가짐을 확인하였다. 특히, 본 발명에 따른 줄기세포가 DDS를 이용하여 궤양성 대장염을 유발시킨 마우스 모델에서 매우 우수한 항염 효과를 보임을 확인하였다. In the examples of the present invention, it was confirmed that the stem cell extract according to the present invention and its fractions have antioxidative and anti-inflammatory activities in vivo as well as in vitro. In particular, it was confirmed that the stem cells according to the present invention exhibit a very excellent anti-inflammatory effect in a mouse model of ulcerative colitis caused by DDS.
이에, 본 발명에서는 상기 줄기세포 파쇄물 또는 배양액을 함유하는 조성물이 항염증 활성을 나타냄을 제시하는 구체적인 실시예가 없다 하더라도, 상기에서 살펴본 바와 같이 그 줄기세포 및 추출물이 항염증 활성을 가지는 것을 확인한바, 본 발명에 따른 줄기세포 자체나 그 파쇄물을 함유한 조성물의 경우에도 항염증 활성을 나타내어 염증성 질환을 예방 또는 치료할 수 있다는 것은 당업계에서 통상의 지식을 가진 자에게 자명하다고 할 것이다.Accordingly, even though there is no specific example in which the composition containing the stem cell lysate or the culture medium exhibits anti-inflammatory activity, it has been confirmed that the stem cells and the extract have anti-inflammatory activity as described above, It will be apparent to those skilled in the art that the stem cell according to the present invention or a composition containing the lysate may exhibit anti-inflammatory activity to prevent or treat an inflammatory disease.
본 발명에 따른 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 유효성분으로 함유하는 항염증 조성물은 이들을 각각 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 포함하여 약학 조성물로 제공될 수 있으며, 상기 줄기세포 등은 질환 및 이의 중증정도, 환자의 연령, 체중, 건강상태, 성별, 투여 경로 및 치료 기간 등에 따라 적절한 약학적으로 유효한 양으로 약학 조성물에 포함될 수 있다. The anti-inflammatory composition containing the stem cell, the extract thereof, the lysate thereof, and the culture thereof according to the present invention as an active ingredient may be used alone or in combination with one or more pharmaceutically acceptable carrier, excipient or diluent And the stem cells can be contained in the pharmaceutical composition in an appropriate pharmacologically effective amount depending on the disease and its severity, the patient's age, body weight, health condition, sex, administration route and treatment period, etc. have.
상기에서 "약학적으로 허용되는"이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다. 상기 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 폴리비닐피롤리톤, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. The term "pharmaceutically acceptable" as used herein refers to a composition that is physiologically acceptable and does not normally cause an allergic reaction such as a gastrointestinal disorder, dizziness, or the like when administered to a human. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Polyvinyl pyrrolitone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
상기 약학 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다. 또한 본 발명의 약학 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 사용하여 제형화될 수 있다. 제형은 분말, 과립, 정제, 에멀젼, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사 용액, 멸균 분말의 형태일 수 있다.
The pharmaceutical composition may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, and an antiseptic agent. The pharmaceutical compositions of the present invention may also be formulated using methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatine capsules, sterile injectable solutions, sterile powders.
아울러, 본 발명은 또 다른 관점에서, 본 발명에 따른 줄기세포, 그 추출물, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 유효성분으로 함유하는 염증의 예방 또는 개선용 기능성 식품에 관한 것이다. In another aspect, the present invention relates to a functional food for preventing or ameliorating inflammation, which contains, as an active ingredient, at least one of stem cells, an extract thereof, a lysate thereof, and a culture thereof according to the present invention.
본원에서 '기능성 식품'이란, 일반 식품에 본 발명에 따른 줄기세포 또는 그 추출물, 파쇄물 및 그 배양물 중 어느 하나 이상을 첨가함으로써 식품의 기능성을 향상시킨 것을 의미한다.
Herein, the term " functional food " means that the function of the food is improved by adding at least one of the stem cells or the extract, the lysate and the culture thereof according to the present invention to the general food.
실시예Example
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
특히, 하기 실시예에서는 은행나무의 형성층 유래 줄기세포, 그 추출물 및 그 분획의 항산화 및 항염증 효과를 확인하였으나, 그 줄기세포 파쇄물 또는 배양액을 사용해서도 유사한 결과를 얻을 수 있다는 것은 당업계에서 통상의 지식을 가진 자에게 자명한 사항이라 할 것이다.
In particular, in the following examples, antioxidative and anti-inflammatory effects of cambium stem cells derived from cambium, extracts thereof and fractions thereof were confirmed. However, it is known in the art that similar results can be obtained by using the stem cell lysate or culture medium It is obvious to those who have the knowledge of.
은행나무의 형성층 유래 줄기세포의 수득Obtain cambium stem cells from cambium
1-1: 식물재료의 준비1-1: Preparation of plant material
은행나무과 은행나무속의 은행나무(Ginkgo biloba , 충청남도 Buyeo, Korea)는 도 1과 같이, Phloroglucinol 염색을 통하여 목부(xylem)와 사부(phloem) 섬유를 관찰할 수 있는데, 이 사이에 형성층(cambium)이 존재함을 확인할 수 있다. 이러한 은행나무로부터 상기 형성층 유래 줄기세포를 수득하기 위하여, 먼저 은행나무의 줄기를 채취한 후, 즉시 항산화제 100 ㎎/L 아스코르브산(L-ascorbic acid, DUCHEFA, The Netherlands) 용액에 침적하여 운송·보관하였다. 이때, 전형성층을 이용하여 동일한 줄기세포를 수득하기 위하여는 줄기 대신 잔가지를 채취한다. Ginkgo and Ginkgo Ginkgo biloba , Buyeo, Korea), as shown in Fig. 1, can be observed through phloroglucinol staining to reveal xylem and phloem fibers, and cambium is present therebetween. In order to obtain the cambium-derived stem cells from such ginkgo, the stem of the ginkgo was firstly harvested and immediately immersed in a solution of 100 mg / L ascorbic acid (DUCHEFA, The Netherlands) Respectively. At this time, in order to obtain the same stem cells using the procambium layer, twigs are collected instead of stem.
그 후, 1% 베노밀(benomyl, Dongbu Hannong Chemical, Korea), 1% 다코닐(daconil, Dongbu Hannong Chemical, Korea), 1% 스트렙토마이신(sterptomycin sulphate, DUCHEFA, The Netherlands), 0.1% 세포탁심(cefotaxime sodium DUCHEFA, The Netherlands)의 혼합용액에 24시간 전처리 후 페놀 화합물(phenolic compound)과 잔존 화학물질을 제거하기 위하여 수돗물(tap water)로 30분간 세척하였다. 그리고, 70% 에탄올(ethanol, DC Chemical, Korea)에 1분, 30% 과산화수소(hydrogen peroxide, LG Chemical, Korea) 15분, 1% CLOROX 용액에 15분, 3% CLOROX용액에 5분 표면 살균 후 3~4회 세척하였다.
Then, 1% benomyl (Dongbu Hannong Chemical, Korea), 1% daconil, Dongbu Hannong Chemical, Korea, 1% streptomycin (DUCHEFA, The Netherlands), 0.1% cefotaxime sodium DUCHEFA, The Netherlands) for 24 hours and then washed with tap water for 30 minutes to remove phenolic compounds and residual chemicals. After sterilization for 1 min in 70% ethanol (DC Chemical, Korea), 15 min in 30% hydrogen peroxide (LG Chemical, Korea), 15 min in 1% CLOROX solution and 5 min in 3% CLOROX solution And washed 3 to 4 times.
1-2: 줄기로부터 형성층 포함 1-2: Formation layer from stem 절편체의Fragmentary 제조조직 분리 Isolate manufacturing tissue
상기 실시예 1-1의 살균과정을 거친 줄기(전형성층 이용시 잔가지)의 형성층이 포함된 수피(bark) 조직을 들어올리면 목부(xylem)에서 쉽게 벗겨졌다. 벗겨진 조직들은 형성층, 사부(phloem), 피층(cortex), 표피(epidermis)를 포함하는 절편체를 구성한다.
The bark tissue containing the formation layer of the stem (the twig in the case of using the procambium layer) subjected to the sterilization process of Example 1-1 was lifted and easily peeled off from the xylem. The peeled tissues constitute an explant comprising the cambium, phloem, cortex, and epidermis.
1-3: 은행나무의 형성층 유래 줄기세포 유도단계1-3: Derivation of cambium stem cells from cambium
상기 실시예 1-2에서 준비한 형성층 포함 절편체는 표 1의 줄기세포 유도배지(배지 1)에 치상하여 배양하였다.
The cambium-containing slices prepared in Example 1-2 were cultured in the stem cell induction medium (medium 1) shown in Table 1.
Inorganic salts
Vitamin
Amino acid
배지에 생장 조절제로서 NAA, IAA, picloram과 같은 옥신(Auxin)은 1~5mg/L의 농도로 첨가할 수 있는데, 바람직하게는 1 mg/L의 농도로 첨가한다. 배양은 25±1℃로 조절된 암실에서 실시되었다.Auxin such as NAA, IAA, and picloram may be added to the medium at a concentration of 1 to 5 mg / L, preferably 1 mg / L. Cultivation was carried out in a dark room controlled at 25 ± 1 ° C.
초기 배양 4~7일째 형성층으로부터 세포 분열이 육안상으로 관찰되고, 배양 15일 이후에 사부·피층 및 표피로 이루어진 층으로부터 탈분화에 의한 무정형의 캘러스가 유도되기 시작하였다. 배양 30일 경과 후 배양된 형성층은 사부를 포함한 층, 즉 무정형의 캘러스층으로부터 분리되기 시작했고(도 2A: 줄기세포(화살표), 사부(pholem) 세포(별표)), 두 층이 자연스럽게 분리될 때까지 기다렸다가 완벽한 분리가 이루어지면 각기 다른 페트리디쉬(petridish)에 분리 배양하였다. 분리 후, 생장률이 좋은 희고 무른 부분을 유도배지와 동일한 새로운 배지로 매 14일째 계대배양하였다. 도 2B는 상기 형성층 유래 줄기세포를 분리하여 3주간 배양한 후의 사진이다.On the 4th to 7th days of the initial culturing, cell division was visually observed from the cambium layer, and after 15 days from the cultivation, amorphous callus induced by dedifferentiation was induced from the calcia, cortex and epidermis. After 30 days of cultivation, the cultured cambium layer began to separate from the layer containing the calcaneus, that is, the amorphous callus layer (Fig. 2A: stem cell (arrow), pholem cell (star)), When complete separation was achieved, the cells were separately cultured in different petridishes. After the separation, the white, loose portion having a good growth rate was subcultured every 14 days with the same new medium as the induction medium. Fig. 2B is a photograph of the cambium-derived stem cells after they are separated and cultured for 3 weeks.
한편, 비교를 위하여 은행나무의 수피(bark) 절편체를 소독한 후 상기 <표 1>의 배지에서 배양하였으며, 그 결과, 도 3B에 나타난 바와 같이, 수피(bark) 절편체는 탈분화에 의해 캘러스를 형성함을 관찰할 수 있었다. 수피 절편체에서 유도된 캘러스는 사부포함조직과 같이 여러 세포들 간의 분열 속도의 차이로 무정형을 이루었고, 생장률이 불안정하며 쉽게 갈변되는 경향을 보였다. 갈변 및 응집되어진 수피 절편체에서 유도된 캘러스는 종국에는 자신이 분비하는 페놀 화합물에 의해 생장이 둔해지다가 종국에는 괴사하였다. 즉, 6개월 후부터 수피로부터 유도된 캘러스들은 유지 및 배양이 어려웠다. 반면, 도 3A에 나타난 바와 같이, 은행나무의 형성층 유래 줄기세포는 장기 배양시 세포의 생장률, 생장 패턴, 응집 정도에 변이 없이 안정적으로 유지되어 대량 배양이 가능했다.
On the other hand, for comparison, bark sections of Ginkgo biloba were disinfected and cultured in the medium of Table 1. As shown in Fig. 3B, the bark fragment was transformed into callus In the case of The callus derived from the bark fragment was amorphous due to the difference in the rate of cleavage between several cells such as calcified tissues, and the growth rate was unstable and easily browsed. The callus induced by browning and agglomerated bark fragment was ultimately dulled by the phenolic compounds secreted by it and eventually necrotized. Namely, callus derived from bark was difficult to maintain and cultivate after 6 months. On the other hand, as shown in FIG. 3A, stem cells derived from the cambium-derived cambium were stably maintained in the growth rate, growth pattern, and degree of coagulation of the cells in a long-term culture, enabling mass culture.
1-4: 은행나무의 형성층 유래 줄기세포의 증식 및 특성 관찰1-4: Growth and characterization of cambium stem cells derived from cambium
실시예 1-3에서 분리한 형성층 유래 줄기세포를 하기 <표 2>의 액상배지가 함유된 플라스크에 넣어 암조건에서 25±1℃에서 100 rpm의 회전 교반기(shaker)에서 배양하였다. 계대배양 주기는 2주일로 고정함으로써 배양세포가 항상 대수생장기 상태에서 높은 활력을 유지할 수 있도록 하였다.The cambium-derived stem cells isolated in Example 1-3 were placed in a flask containing the liquid medium of Table 2, and cultured in a shaker at 100 rpm at 25 ± 1 ° C under dark conditions. The subculture period was fixed to 2 weeks, so that the cultured cells were always able to maintain high vigor in the algebraic growth state.
Inorganic salts
Vitamin
Amino acid
광학 현미경 BX41(Olympus, Japan) 하에서 세포 응집정도를 살펴 볼 때, 본 발명에 따른 줄기세포는 도 4A에 나타난 바와 같이, 현탁배양 시 많은 수의 단세포를 포함하며, 일부는 작은 사이즈의 세포 집합체로 존재하는 것을 확인할 수 있었으나, 대조군인 은행나무의 체세포(수피 조직에서 유도된 캘러스)의 경우, 도 4B에 나타난 바와 같이 응집됨을 관찰할 수 있었다. As shown in FIG. 4A, the stem cell according to the present invention includes a large number of single cells in suspension culture, and a small number of cell aggregates in suspension culture under an optical microscope BX41 (Olympus, Japan) But the somatic cells (callus derived from the bark tissue) of the control group, Ginkgo biloba, were observed to aggregate as shown in Fig. 4B.
한편, 도 5A에 나타난 바와 같이, 본 발명에 따른 줄기세포는 다수개의 액포(vacuole)를 가지는 형태학적 특징을 관찰할 수 있었다. 이러한 특징은 식물체 내에 존재하는 미분화된 세포에서 압력 등과 같은 원인에 의하여 나타나는 특징으로서, 이에 본 발명에 따른 줄기세포는 미분화상태임을 확인할 수 있었다. 일반 은행나무의 체세포(수피 조직에서 유도한 캘러스)의 경우, 도 5B에 나타난 바와 같이, 이러한 특징을 확인할 수 없었다. 이를 더 상세히 살펴보기 위하여, 액포를 neutral red로 염색한 결과, 본 발명에 따른 줄기세포는 도 6A에 나타난 바와 같이 적색의 다수개의 작은 액포(vacuole)를 확인할 수 있었으며, 일반 은행나무의 체세포(수피 조직에서 유도한 캘러스)의 경우 도 6B에 나타난 바와 같이, 하나의 큰 중심액포가 존재함을 확인할 수 있었다. Meanwhile, as shown in FIG. 5A, the stem cells according to the present invention were able to observe a morphological characteristic having a plurality of vacuoles. This feature is a characteristic of the undifferentiated cells existing in the plant due to causes such as pressure and the like, and thus it can be confirmed that the stem cells according to the present invention are undifferentiated. In the case of somatic cells of the common ginkgo (callus derived from bark tissue), such characteristics could not be confirmed, as shown in Fig. 5B. As a result of staining the vacuole with neutral red, the stem cells according to the present invention were able to identify a plurality of red vacuole, as shown in FIG. 6A, and were able to identify somatic cells Tissue-derived callus), as shown in FIG. 6B, it was confirmed that one large central vacuole was present.
한편, 본 발명에 따른 줄기세포는 광학현미경 BX41(Olympus, Japan)를 통해 관찰한 결과, 움직임 면에서 활성이 매우 높은 미토콘드리아를 다수 개 관찰할 수 있었다. 도 7A는 본 발명에 따른 줄기세포가 다수개의 미토콘드리아를 가짐을 나타내는 것으로 화살표는 미토콘드리아를 나타낸다. 이에 반하여, 일반 은행나무의 체세포(수피 조직에서 유도한 캘러스)의 경우, 도 7B에 나타난 바와 같이, 이러한 특징을 확인할 수 없었다. Meanwhile, the stem cells according to the present invention were observed through an optical microscope BX41 (Olympus, Japan), and a number of mitochondria highly active on the movement plane could be observed. FIG. 7A shows that stem cells according to the present invention have a plurality of mitochondria, and arrows indicate mitochondria. On the other hand, in the case of somatic cells (callus derived from bark tissue) of common ginkgo, these characteristics could not be confirmed as shown in Fig. 7B.
한편, 배양기간별 증식속도를 측정하기 위하여, 3L의 내용적을 갖는 공기 부양형 생물반응기(airlift bioreactor, Samsung Science, Korea)를 이용하여 세포배양물의 생장속도를 측정한 결과, 도 8에 나타난 바와 같이, 1주일 배양 시 2배, 2주일 배양 시 총 3배의 생장률을 확인할 수 있었다. 이때, 배지는 <표 2>의 액상배지를 사용하였고, 암조건에서 25±1℃로 일정하게 유지하였다. 아울러, 이와 동일한 배지와 조건으로 3L의 공기 부양형 생물반응기에서 은행나무 수피조직에서 유도한 캘러스와 본 발명에 따른 은행나무의 형성층 유래 줄기세포를 배양하여 서로 비교하였다. On the other hand, in order to measure the growth rate per culture period, the growth rate of the cell culture was measured using an air floating bioreactor (Samsung Science, Korea) having a volume content of 3 L. As a result, When we cultured for 1 week, it was able to confirm the growth rate of 2 times and 3 weeks for 2 weeks. At this time, the medium used in the liquid medium of Table 2 was kept at 25 ± 1 ° C under the dark condition. In addition, the callus derived from gingko bark tissue and the cambium stem cell derived from Ginkgo biloba according to the present invention were cultured in a 3L air floating type bioreactor under the same conditions and conditions, and compared with each other.
그 결과, <표 3> 및 도 9에 나타난 바와 같이, 은행나무 수피조직에서 유도한 캘러스의 생장속도는 2.3배이고, 생장지수 (GI) (growth index = (maximum DCW - initial DCW) / initial DCW )는 1.3에 불과하였으나, 본 발명에 따른 형성층 유래 줄기세포는 생장속도가 3.1배이고, 생장지수 (GI)가 2.27로 은행나무 수피조직에서 유도한 캘러스에 비하여 높음을 확인할 수 있었다. 통상 반응기의 경우 반응기 내에서의 생장고리 (growth ring) 생성과 배양중의 식물 배양체 응집성과 세포벽이 단단하여 전단 스트레스에 대한 민감성으로 세포 생존율(cell viability)이 급격히 감소하나, 형성층 유래 줄기세포 배양물은 생물반응기 내의 생장고리 면적을 아주 작게 형성하고, 배양기에 간단한 자극을 주어 배지를 움직여주면 내벽의 링(ring)이 간단하게 해소되었다. 또한 응집이 작고, 많은 액포(vacuole)를 가지고 있어 전단 스트레스에 대한 민감성이 약하여 세포 생존율(cell viability)이 거의 감소하지 않았다.As a result, as shown in Table 3 and FIG. 9, the growth rate of callus derived from gingko bark tissue was 2.3 times, and the growth index (GI) (growth index = (maximum DCW - initial DCW) / initial DCW) Was found to be 1.3. However, it was found that the cambium-derived stem cells according to the present invention had a growth rate of 3.1 times and a growth index (GI) of 2.27, which was higher than that of callus derived from ginkgo biloba. Generally, in the case of a reactor, the cell viability is rapidly reduced due to the generation of a growth ring in the reactor, sensitivity to shear stress due to cohesion of the plant culture and cell wall during culturing, but the stem cell culture Formed a very small area of growth rings in the bioreactor, and the ring on the inner wall was easily solved by moving the medium with a simple stimulus in the incubator. In addition, the cohesion was small and the cell viability was hardly decreased due to its low sensitivity to shear stress due to its large vacuole.
아울러, <표 4> 및 도 10에서 볼 수 있듯이, 3 L 공기부양형 생물반응기, 20 L 공기부양형 생물반응기 및 250 L 공기부양형 생물반응기에서 10일간 배양한 결과, 250 L와 같이 대량배양시에도 증식됨을 확인할 수 있었으며, 250 L의 대량배양시 오히려 리터당 건조세포 양이 증가한 것으로 나타났다. In addition, as shown in Table 4 and FIG. 10, when the cells were cultured in a 3 L air-floating bioreactor, a 20 L air-floating bioreactor and a 250 L air-floating bioreactor for 10 days, And the amount of dry cell per liter was increased in the case of mass culture of 250 L.
즉, 본 발명에 따른 형성층 유래 줄기세포는 대량배양을 위한 생물 반응기에서 전단 스트레스에 대하여 낮은 민감성을 가지므로, 생물반응기 내에서 급속 대량 생장이 가능함을 확인하였다. 따라서, 본 발명에 따른 형성층 유래 줄기세포가 은행나무의 탈분화된 캘러스 유래 세포주에 비하여 전단스트레스에 대하여 낮은 민감성을 가짐을 알 수 있었다.That is, it was confirmed that the cambium-derived stem cells according to the present invention have a low sensitivity to shear stress in a bioreactor for mass culture, so that rapid mass growth is possible in a bioreactor. Thus, it was found that the cambium-derived stem cells according to the present invention had a lower sensitivity to shear stress than the dedifferentiated callus-derived cell line of Ginkgo biloba.
한편, 은행나무 수피조직에서 유도한 캘러스와 본 발명에 따른 은행나무 형성층 유래 줄기세포에 대하여 동결보존을 실시하였다. 현탁배양물은 배양 6일에서 8일 된 것을 사용하며, 동결보존제는 0.5 M glycerol (DUCHEFA, The Netherlands)과 0.5 M DMSO (DUCHEFA, The Netherlands)와 1 M sucrose (DUCHEFA, The Netherlands) 포함된 배지이고, 5 mL cryovial(Duran, USA)에 옮겼다. 동결보존제에 처리되는 세포 접종량은 200 mg/mL 이다. 동결보존제 처리된 현탁세포는 30분간 냉동고에 유지한 다음 deep freezer에 3시간 보관 후 액체질소에 침지시켜 냉동시켰다. On the other hand, the callus derived from the ginkgo biloba and the stem cells derived from the ginkgo biloba according to the present invention were cryopreserved. Suspension cultures were used for 6 to 8 days of incubation. The cryopreservation medium was a medium containing 0.5 M glycerol (DUCHEFA, The Netherlands), 0.5 M DMSO (DUCHEFA, The Netherlands) and 1 M sucrose (DUCHEFA, The Netherlands) , And transferred to 5 mL cryovial (Duran, USA). The amount of cells inoculated into the cryopreservative is 200 mg / mL. The cryopreserved suspension cells were kept in a freezer for 30 minutes, then stored in a deep freezer for 3 hours, then immersed in liquid nitrogen for freezing.
그 후 해빙을 위하여 액체질소에 20분 이상 유지된 배양세포를 꺼내어 40℃ 항온수조에 넣고 1~2분간 해동시켰다. 세포 재생장을 위해, 세포 현탁액을 무균상태의 깔때기 및 여과지를 사용하였다. 여과된 세포는 filter paper가 포함된 고형생장배지상에 적용시키고 30분간 실온에서 안정화 시킨 다음, 다시 신선한 고형생장배지로 다시 옮겨졌다.After that, cultured cells kept in liquid nitrogen for more than 20 minutes were taken out for thawing, placed in a constant temperature water bath at 40 ° C, and thawed for 1 to 2 minutes. For cell regeneration, the cell suspension was used as a sterilized funnel and filter paper. The filtered cells were applied onto a solid growth medium containing filter paper, stabilized at room temperature for 30 minutes, and then transferred again to fresh solid growth medium.
Stem cell
18.87
Callus
2.87
그 결과, 도 11 및 표 5에서 볼 수 있듯이, 은행나무 수피조직에서 유도한 캘러스는 본 발명의 은행나무 형성층 유래 줄기세포에 비하여 매우 낮은 생존율을 보임을 확인할 수 있었다. As a result, as shown in FIG. 11 and Table 5, it was confirmed that the callus induced from the ginkgo bark tissue had a very low survival rate as compared with the stem cells derived from the ginkgo seedlings of the present invention.
아울러, 식물줄기세포를 특징짓는 특성에는 자가재생능력(self renewal)이외에 분화능(pluripotency)이 있다. 이에 은행나무 형성층 유래 줄기세포의 도관요소 분화를 유도하기 위하여, 생장조절제가 포함된 MS medium 조건에서 25±1℃, 암조건에서 배양한 결과, 형성층 유래 줄기세포로부터 도관요소가 분화됨을 확인할 수 있었다.
In addition, the characteristic features of plant stem cells include pluripotency in addition to self renewal ability. In order to induce the differentiation of stem cells from gingko cambium-derived stem cells, it was confirmed that the ductal factor was differentiated from cambium-derived stem cells by culturing under MS medium containing growth regulator at 25 ± 1 ° C. .
1-5: 1-5: 엘리시터의Elicitor's 처리 process
실시예 1-4와 같이 14일간 현탁배양한 줄기세포를 멸균수에 원당 3~5 %(g/L) 및 메틸 자스모네이트 100 μM를 첨가한 배지에서 14일간 암배양한 줄기세포를 수거하여 다음의 실험을 수행하였다.
Stem cells cultured for 14 days in a medium supplemented with 3-5% (g / L) of raw sugar and 100 μM of methyl jasmonate were added to sterilized water for 14 days as in Example 1-4. The following experiment was conducted.
은행나무의 형성층 유래 줄기세포의 에탄올 추출물 제조Production of ethanol extract of cambium stem cells derived from cambium
2-1: 에탄올 추출물의 제조2-1: Preparation of ethanol extract
(ⅰ) 배양액을 제거시킨 상기 실시예 1에서 분리된 줄기세포 2 g에 50 mL의 80% 에탄올을 섞고, 15℃에서 48시간 진탕하였다.(I) 50 g of 80% ethanol was added to 2 g of the stem cells isolated in Example 1 from which the culture medium had been removed, and the mixture was shaken at 15 DEG C for 48 hours.
(ⅱ) 진탕 후 생성된 상등액을 동결건조시키고, 에탄올 추출물을 얻었다.
(Ii) The supernatant produced after shaking was lyophilized to obtain an ethanol extract.
2-2: 2-2: DMSODMSO ( ( dimethyldimethyl sulfoxidesulfoxide ) 추출물의 제조) Preparation of extract
(ⅰ) 배양액을 제거시킨 상기 실시예 1에서 분리된 줄기세포 500 g에 500 mL의 DMSO를 가하여 50℃에서 6시간 교반시키면서 용해시켰다.(I) 500 g of the stem cells isolated in Example 1, from which the culture solution had been removed, 500 mL of DMSO was added and dissolved at 50 DEG C for 6 hours with stirring.
(ⅱ) 상기 용해 후, 3,000 ×g에서 10분간 원심분리시켜 상층액을 취함으로써 DMSO 가용성물질을 얻었다.(Ii) After the dissolution, the supernatant was taken by centrifugation at 3,000 x g for 10 minutes to obtain a DMSO-soluble substance.
(ⅲ) 상기에서 얻은 DMSO 가용성물질을 회전진공농축기를 이용하여 농축하였다. (Iii) The DMSO-soluble material obtained above was concentrated using a rotary vacuum concentrator.
(ⅳ) 농축시료를 동결건조기를 이용하여 건조시키고 DMSO 추출물을 얻었다.
(Iv) Concentrated samples were dried using a freeze dryer to obtain DMSO extract.
2-3: 증류수 추출물, 메탄올 추출물 및 아세톤 추출물의 제조2-3: Preparation of distilled water extract, methanol extract and acetone extract
실시예 1에서 제조된 줄기세포로부터 다음과 같이 단계별로 유효물질을 추출하였다.From the stem cells prepared in Example 1, the active substances were extracted in the following steps.
(ⅰ) 배양액을 제거시킨 상기 실시예 1에서 분리된 세포주 500 g에 500 mL의 증류수를 가하여 50℃에서 6시간 교반시키면서 용해시켰다.(I) 500 g of the cell line isolated in Example 1 from which the culture solution was removed was dissolved in 500 mL of distilled water while stirring at 50 DEG C for 6 hours.
(ⅱ) 상기 용해 후, 3,000 ×g에서 10분간 원심분리시켜 상층액을 취함으로써 증류수 가용성물질을 얻었다.(Ii) After the dissolution, the supernatant was taken by centrifugation at 3,000 x g for 10 minutes to obtain a distilled water-soluble substance.
(ⅲ) 상기 증류수 가용성 물질을 얻은 후, 남은 증류수 불용성물질에 500 mL의 메탄올(methanol)을 첨가시켜 실온에서 6시간 교반하여 용해시켰다.(Iii) After obtaining the distilled water-soluble substance, 500 mL of methanol was added to the remaining distilled water-insoluble matter, and the mixture was stirred and dissolved at room temperature for 6 hours.
(ⅳ) 상기 용해 후, 3,000 ×g에서 10분간 원심분리 시켜 상층액을 취함으로써 메탄올 가용성물질을 얻었다.(Iv) After the dissolution, the mixture was centrifuged at 3,000 x g for 10 minutes to obtain a supernatant, thereby obtaining a methanol-soluble substance.
(ⅴ) 상기 메탄올 가용성물질을 얻은 후, 남은 메탄올 불용성물질에 500 mL의 아세톤(acetone)을 첨가시켜 실온에서 6시간 교반하여 용해시켰다.(V) After obtaining the methanol-soluble substance, 500 mL of acetone was added to the remaining methanol insoluble matter, and the mixture was stirred and dissolved at room temperature for 6 hours.
(ⅵ) 상기 용해 후, 3,000 ×g에서 10분간 원심분리 시켜 상층액을 취함으로써 아세톤 가용성물질을 얻었다. (Vi) After the dissolution, the mixture was centrifuged at 3,000 xg for 10 minutes to obtain an acetone-soluble substance.
(ⅶ) 상기에서 얻은 증류수, methanol, acetone 가용성물질을 회전진공농축기를 이용하여 농축하였다.(Ⅶ) The distilled water, methanol, and acetone soluble material obtained above were concentrated using a rotary vacuum concentrator.
(ⅷ) 농축시료를 동결건조기를 이용하여 건조시키고 세포배양액, 메탄올, 아세톤에 녹여 증류수 추출물, 메탄올 추출물, 아세톤 추출물을 얻었다.
(Ⅷ) Concentrated samples were dried using a freeze dryer and dissolved in cell culture medium, methanol and acetone to obtain distilled water extract, methanol extract and acetone extract.
은행나무의 형성층 유래 줄기세포의 추출물 분획시료의 제조Preparation of Extract Fractionated Samples of Stem Cells Derived from Cambium
실시예 2-1에서 제조한 에탄올 추출물로부터 다음과 같이 분획시료를 제조하였다. A fraction sample was prepared from the ethanol extract prepared in Example 2-1 as follows.
에탄올 추출물에서 분획 시료를 준비하기 위해서는 column chromatography (Sephadex LH-20 column, 15 x 1260 mm, bead volume: 222 mL)를 시행하였다. 상기한 바와 같이 준비된 CMCs 80% ethanol 추출물 4.2g으로부터 활성물질을 분리하기 위하여 Sephadex LH-20(150 × 1260 mm, 100% methanol)을 이용하여 gel filtration을 수행 하였다. 분당 유속 0.8ml (SV=0.23)로 분획하여 총 120개의 분획을 얻었다. 각 분획시료는 thin layer chromatography (TLC) 분석을 통하여 Fr.Ⅰ~ Fr.Ⅶ 까지 7개 fraction (도 12)으로 정리하고 각 분획 별로 하기의 활성 검정에서 사용하였다. To prepare the fractions from the ethanol extracts, column chromatography (Sephadex LH-20 column, 15 x 1260 mm, bead volume: 222 mL) was performed. Gel filtration was performed using Sephadex LH-20 (150 × 1260 mm, 100% methanol) to separate the active material from the prepared 4.2 g of 80% ethanol extract of CMCs. And a flow rate per minute of 0.8 ml (SV = 0.23) to obtain a total of 120 fractions. Each fraction was analyzed by thin layer chromatography (TLC) using 7 fractions (from Fr. I to Fr. VII) (Fig. 12).
Fr.Ⅰ(#1) : ( Fr. 1 ~ 7) , 2.4612gFr.I (# 1): (Fr. 1-7), 2.4612 g
Fr.Ⅱ(#2) : ( Fr. 8~ 11) , 0.199gFr.II (# 2): (Fr. 8-11), 0.199 g
Fr.Ⅲ(#3) : ( Fr.12~ 15) , 0.141g Fr.III (# 3): (Fr.12-15), 0.141 g
Fr.Ⅳ(#4) : ( Fr.16~ 23) , 0.2265gFr. IV (# 4): (Fr. 16-23), 0.2265 g
Fr.Ⅴ(#5) : ( Fr.24~ 30) , 0.1785gFr. V (# 5): (Fr. 24 to 30), 0.1785 g
Fr.Ⅵ(#6) : ( Fr.31~ 60) , 0.3036gFr. VI (# 6): (Fr.31-60), 0.3036 g
Fr.Ⅶ(#7) : ( Fr.61~120) , 0.2329g
Fr. VII (# 7): (Fr.61-120), 0.2329 g
은행나무의 형성층 유래 줄기세포의 추출물 분획의 Extract fraction of cambium stem cells derived from cambium inin vitrovitro 항산화 효과 확인 Identify antioxidant effect
4-1: 4-1: HypoxanthineHypoxanthine // xanthinexanthine oxidaseoxidase assayassay 를 통한 분획시료의 항산화 활성 측정Antioxidant activity of fractionated samples
실시예 2-1에서 수득한 에탄올 추출물 또는 실시예 3에서 제조한 각 은행나무의 형성층 유래 줄기세포(Cambium meristem cells, CMCs) 추출물 분획시료와 반응액(30 mM EDTA (pH 7.4), 30 mM xanthine, 1.42 mM NBT (nitro blue tetrazolium))을 50 mM PBS에 넣어준 후 xanthine oxidase (0.5 U/mL)를 첨가하여, 15분 동안 반응시켰다. 그리고 용액의 흡광도를 560 nm에서 측정하여 분획시료가 어느 정도의 항산화 효과를 가지는지 그 활성 정도를 (superoxide radical 생성 저해 정도를) 대조군과 비교하여 측정하였다. 대조군으로는 항산화제를 넣지 않고 xanthine oxidase만을 처리하였을 때 반응의 결과 나타나는 흡광도를 측정하여 결정하였으며, 각 분획 시료의 superoxide radical scavenging activity를 백분율로 환산하여 결정하였다. (30 mM EDTA (pH 7.4), 30 mM xanthine (CMC)) and the extracts of the extracts of Cambium meristem cells (CMCs) obtained from Example 2-1 or the Ginkgo biloba prepared in Example 3 , 1.42 mM NBT (nitro blue tetrazolium)) was added to 50 mM PBS, followed by addition of xanthine oxidase (0.5 U / mL) for 15 minutes. The absorbance of the solution was measured at 560 nm, and the extent of the antioxidative effect of the fractionated sample was measured (the degree of inhibition of superoxide radical formation) compared with the control group. As a control, the absorbance of xanthine oxidase treated without antioxidant treatment was determined by measuring the absorbance and the superoxide radical scavenging activity of each fraction was determined as a percentage.
(㎍/mL)density
(쨉 g / mL)
그 결과, 표 6에 나타난 바와 같이, 7개의 분획 시료 중 분획 #3, #4, #5, 그리고 #6에서 10 ㎍/mL 농도를 사용하였을 때 70% 이상의 저해 효과를 보여 이들 분획이 다른 분획에 비하여 높은 superoxide radical scavenging activity를 가짐을 알 수 있었다.
As a result, as shown in Table 6, when the concentration of 10 μg / mL was used in the
4-2: 4-2: DeoxyriboseDeoxyribose assayassay 를 통한 분획시료의 Of the fractionated sample hydroxylhydroxyl radicalradical scavengingscavenging activity 측정 activity measurement
유리 tube 안에 100 μM FeCl3, 104 μM EDTA (pH 7.4)를 넣어 10분간 반응시킨 다음 1.5 mM 과산화수소, 2.5 mM deoxyribose, 100 μM vitamin C를 넣어준 후 실시예 2-1의 에탄올 추출물 또는 실시예 3의 각 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 분획시료를 넣어 37℃에서 1시간 동안 반응시켰다. 각각의 반응시료에 1.5% 2-TBA (2-thiobarbituric acid)와 2.8% TCA (trichloroacetic acid)를 넣어 잘 혼합한 다음 80℃에서 30분 동안 반응시킨 후 532 nm에서 흡광도를 측정하였다. Fenton system (Fe3 +-ascorbate-EDTA-H2O2)으로 발생하는 hydroxyl radical에 의해 deoxyribose는 분해되며, 산성 상태에서 가열에 의해 malonaldehyde가 생성되게 된다. 생성된 malonaldehyde는 thiobarbituric acid와 반응하여 핑크색의 chromogen을 형성함으로써 흡광도를 증가시킨다. 따라서 시료 내 hydroxyl radical 소거활성이 존재하는 경우 시료 첨가에 의해 deoxyribose의 분해가 억제되며 흡광도가 감소하게 된다. 시료의 hydroxyl radical 소거활성은 시료 무첨가군의 흡광도 변화를 100%로 기준하여 시료 첨가군의 흡광도 변화를 hydroxyl radical 생성 억제율로 표시하였다.100 μM FeCl 3 and 104 μM EDTA (pH 7.4) were added to the glass tube, followed by reaction for 10 minutes. Then, 1.5 mM hydrogen peroxide, 2.5 mM deoxyribose, and 100 μM vitamin C were added thereto and the ethanol extract of Example 2-1 or Example 3 (CMCs) extracts from the cambium of each ginkgo were added and incubated at 37 ° C for 1 hour. Each reaction sample was mixed well with 1.5% 2-TBA (2-thiobarbituric acid) and 2.8% TCA (trichloroacetic acid), reacted at 80 ° C for 30 minutes and absorbance was measured at 532 nm. Deoxyribose is decomposed by hydroxyl radicals generated by Fenton system (Fe 3 + -ascorbate-EDTA-H 2 O 2 ) and malonaldehyde is produced by heating under acidic conditions. The resulting malonaldehyde reacts with thiobarbituric acid to form a pink chromogen, which increases the absorbance. Therefore, in the presence of hydroxyl radical scavenging activity in the sample, decomposition of deoxyribose is inhibited by the addition of the sample and the absorbance decreases. The hydroxyl radical scavenging activity of the sample was expressed as the inhibition rate of hydroxyl radical formation by the change of absorbance of the sample addition group based on the change of absorbance of the group without addition of the sample to 100%.
(㎍/mL)density
(쨉 g / mL)
그 결과, 표 7에 나타난 바와 같이, 7개의 분획 시료 중 분획 #4, #5, #6, 그리고 #7에서 100 μg/mL 농도를 사용하였을 때 70% 이상의 hydroxyl radical scavenging activity를 가짐을 알 수 있었다.As a result, as shown in Table 7, when the concentration of 100 μg / mL was used in the
이러한 결과에 근거하여 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 7개의 분획 시료 중 두 assay에서 공통적으로 높은 in vitro 항산화 효과를 보이는 #4, #5, 그리고 #6 분획시료를 본격적인 in vitro 항염증 효과 연구의 대상 시료로 선정하였다.
Forming the origin of ginkgo on the basis of these results stem cells (CMCs) are common in a high assay of extracts from two to seven fraction
은행나무의 형성층 유래 줄기세포의 추출물 분획 시료 처리에 의한 생존율 조사Survival rate of cambium stem cells from cambium-derived stem cells by treatment with extract fraction
실시예 3의 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 분획시료의 in vitro 항염증 효과는 mouse macrophage cell line인 RAW 264.7 세포주를 사용하여 확인하였다. 이에 각 분획시료가 가지는 세포 독성을 먼저 확인하고자 3-(4,5-dimethylthiazole-2yl-)-2,5-diphenyl tetrazolium bromide (MTT)를 이용한 세포 생존율을 조사하였다.The in vitro antiinflammatory effect of the extract layer fractions of cambial stem cell (CMCs) extracts of Example 3 was confirmed using a mouse macrophage cell line RAW 264.7 cell line. To determine the cytotoxicity of each fraction sample, cell viability was investigated using 3- (4,5-dimethylthiazole-2yl-) - 2,5-diphenyl tetrazolium bromide (MTT).
이에 먼저 각 분획시료와 실시예 2-1의 에탄올 추출물(crude extract, CE)를 50 μg/mL 농도로 먼저 처리한 다음 LPS를 1 μg/mL 농도로 처리하여 24시간 배양하였다. 이후 MTT assay를 이용하여 세포 생존율을 측정한 결과, 도 13에 나타난 바와 같이, CE 처리군과 LPS 처리군에서는 90% 내외, 그리고 각 분획시료 처리군에서는 50% 내외의 생존율을 보였다. First, each fraction sample and crude extract (CE) of Example 2-1 were first treated at a concentration of 50 μg / mL and then treated with LPS at a concentration of 1 μg / mL for 24 hours. As shown in FIG. 13, the survival rate of the cells treated with MTT assay was about 90% in the CE treatment group and in the LPS treatment group, and about 50% in the each fraction treatment group, as shown in FIG.
이는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물(CE)에 비하여 각 분획 시료에서 약간의 세포 독성이 있음을 의미하며, 아마도 유효 성분 혹은 부수적으로 시료에 존재하는 성분의 농축효과에 의하여 일부 독성이 보여지는 것으로 판단되었다. 따라서 향후 분획 추출물 혹은 유효 성분의 실재 적용 시 생리활성 성분의 조화를 이루는 정확한 적용량의 결정이 필수적으로 필요할 것으로 생각되었다.
This means that the cytotoxicity of each fraction is slightly cytotoxic compared to the cambium stem cell (CMC) extract (CE) of Ginkgo biloba, and it is presumed that some toxicity due to the enrichment effect of the active ingredient, or incidentally, It was judged to be shown. Therefore, it is considered necessary to determine the exact amount of application of the fraction extract or active ingredient in order to harmonize the physiologically active ingredient.
은행나무의 형성층 유래 줄기세포의 추출물 분획 시료의 항염증 효능 확인Identification of Anti-Inflammatory Activity of Extracted Fraction of Safflower Stem Cells from Ginkgo
6-1: 6-1: LPSLPS 의 of RAWRAW 264.7 264.7 macrophagemacrophage cellcell lineline 처리에 의하여 생성되는 Process nitricnitric oxide ( oxide ( NONO )에 대한 은행나무의 형성층 유래 줄기세포() Stem cells from the cambium of cambium CMCsCMCs ) 추출물 분획 시료의 저해 효과) Inhibitory effect of extract fraction fractions
LPS를 처리한 macrophage cell은 염증반응 측정의 유용한 모델로 다양하게 사용되고 있다. 특히, 이 모델에서 염증에 관련된 cytokine, MAP kinase, 그리고 NF-kB activation 등이 indicator로서 측정되고 있다. 특히, NO는 다양한 염증반응의 indicator인 iNOS에 의하여 증가하기 때문에 LPS가 처리된 macrophage cell line에서의 염증 반응에 있어서 가장 기초적으로 측정되어야 하는 물질이다. 이에 실시예 3의 각 분획시료와 실시예 2-1의 에탄올 추출물 (crude extract)를 50 μg/mL 농도로 먼저 처리한 다음 LPS를 1 μg/mL 농도로 처리하여 24시간 배양하였으며, 이후 생성된 NO의 양을 nitrite 농도를 측정하여 확인하였다LPS-treated macrophage cells have been widely used as useful models for measuring inflammatory responses. In particular, inflammation-related cytokines, MAP kinases, and NF-kB activation are measured as indicators in this model. In particular, NO is the most fundamental measure of the inflammatory response in the macrophage cell line treated with LPS, since it is increased by iNOS, an indicator of various inflammatory responses. Each of the fraction samples of Example 3 and crude extract of Example 2-1 was first treated at a concentration of 50 μg / mL and then treated with LPS at a concentration of 1 μg / mL for 24 hours. The amount of NO was confirmed by measuring the nitrite concentration
그 결과, 도 14에 나타난 바와 같이, RAW 264.7 macrophage cell line에 은행나무의 형성층 유래 줄기세포(CMCs) 추출물(CE)과 각 분획 시료를 각각 50 μg/mL 농도로 처리한 다음 1 μg/mL의 LPS를 첨가하여 24시간 배양한 결과 LPS에 의하여 유도되는 NO 농도가 CMCs CE 뿐만 아니라 모든 추출물 분획 처리에 의하여 통계적으로 유의한 수준(SigmaPlot, t- test)으로 감소함을 알 수 있었다. As a result, as shown in FIG. 14, the cambium stem cell (CMC) extract (CE) and each fraction were treated at a concentration of 50 μg / mL in a RAW 264.7 macrophage cell line, When LPS was added for 24 hours, it was found that the concentration of NO induced by LPS decreased to a statistically significant level (SigmaPlot, t- test ) by treatment with all extract fractions as well as CMCs CE.
도 13의 결과를 볼 때, 각 분획 시료가 실험에 사용된 macrophage cell line에 약한 세포독성을 보였기 때문에 CMCs 시료의 항염증 효과가 세포에 대한 독성일 수도 있다는 우려가 제기될 수도 있으나, 각 시료가 보이는 NO 활성 저해 효과(도 14)와 MTT assay 결과(도 13)의 세포 활성 저해 수준이 일치 않음을 보아 은행나무의 형성층 유래 줄기세포(CMCs) 추출 분획 시료의 세포에 대한 독성이 NO 활성 저해의 원인이 아님을 알 수 있었다. 따라서 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 효과적인 항염증 활성을 가질 것으로 예측되었다.
From the results shown in FIG. 13, there is a fear that the anti-inflammatory effect of the CMCs may be toxic to the cells because each fraction sample showed weak cytotoxicity on the macrophage cell line used in the experiment. However, The cytotoxicity of CMCs extracted from cambium stem cells from ginkgo trees was significantly inhibited by inhibition of NO activity (Fig. 14) and MTT assay (Fig. 13) It was not the cause. Therefore, stem cells from cambium-derived stem cells (CMCs) were expected to have an effective anti-inflammatory activity.
6-2: 6-2: LPSLPS 의 of RAWRAW 264.7 264.7 macrophagemacrophage cellcell lineline 처리에 의하여 발현되는 cyclooxygenase-2 ( The expression of cyclooxygenase-2 ( COXCOX -2)와 -2) and iNOSiNOS 유전자에 대한 For the gene CMCsCMCs 추출물 분획 시료의 저해 효과 Inhibitory effect of extract fraction
상술한 바와 같이, 대부분의 염증반응에서 NO의 발현은 중요 indicator이며, NO의 발현에는 iNOS 효소의 작용에 의한 것으로 알려져 있다. 따라서 iNOS 유전자의 발현은 염증반응 측정의 필수적인 요소라고 할 수 있다. 또한, COX-2 역시 염증반응 유도 여부의 가장 중요한 indicator 중 하나로 알려지고 있다. 따라서, LPS를 처리한 RAW 264.7 macrophage cell line에서 발현되는 iNOS 및 COX-2 유전자가 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 분획의 처리에 의하여 얼마나 저해되는지 확인하여 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 분획의 항염증 효과를 확인하고자 하였다. As described above, the expression of NO in most inflammatory reactions is an important indicator, and the expression of NO is known to be caused by the action of iNOS enzyme. Therefore, expression of iNOS gene is an essential element of inflammatory response measurement. COX-2 is also known to be one of the most important indicators of inflammatory response. Therefore, we investigated how the iNOS and COX-2 genes expressed in the RAW 264.7 macrophage cell line treated with LPS were inhibited by the cambium-derived stem cell (CMCs) extract fraction, CMCs) extract fraction.
이에 RAW 264.7 cell에 실시예 3의 각 분획시료와 실시예 2-1의 에탄올 추출물(crude extract, CE)를 50 μg/mL 농도로 먼저 처리한 다음, LPS를 1 μg/mL 농도로 처리하여 24시간 배양하였으며, 이후 발현된 COX-2와 iNOS의 양을 RT-PCR을 이용하여 확인하였다. Then, each fraction sample of Example 3 and crude extract (CE) of Example 2-1 were firstly treated at a concentration of 50 μg / mL in RAW 264.7 cells and treated with 1 μg / mL of LPS to obtain 24 And the amounts of COX-2 and iNOS expressed thereafter were confirmed by RT-PCR.
이때, RT-PCR은 다음과 같이 수행하였다. At this time, RT-PCR was performed as follows.
먼저, 상기 배양한 RAW264.7 cell을 eppendorf tube에 수거하여 PBS를 넣어 세척한 다음 total RNA extraction kit을 사용하여 total cellular RNA를 추출하였다. 먼저 Trizol을 넣고 상온에서 5분 동안 cell을 lysis시킨 후 chloroform을 넣고 상온에서 15초 동안 vortex하였다. 2~3분 후 4℃에서 15분간 12,000 rpm으로 원심분리시킨 후 상등액을 조심히 취하여 isopropanol을 넣어 상온에서 10분 동안 반응시켰으며, 4℃에서 10분간 12,000 rpm으로 원심분리 하여 RNA를 침전시킨 후 상등액은 버렸다. 80% 에탄올을 사용하여 RNA pellet을 washing (4℃에서 5분 동안 12,000 rpm으로 원심분리)한 후 air dry 시켜 DEPC H2O을 넣어 RNA를 추출하였다. 총 RNA를 전기영동으로 확인 후 spectrophotometer를 이용하여 RNA를 정량한 다음 first-strand cDNA를 합성하였다. First, the cultured RAW 264.7 cells were collected in an eppendorf tube, washed with PBS, and total cellular RNA was extracted using a total RNA extraction kit. First, Trizol was added and the cells were lysed at room temperature for 5 minutes. Then, chloroform was added and vortexed at room temperature for 15 seconds. After 2-3 minutes, centrifugation was carried out at 12,000 rpm at 4 ° C for 15 minutes. The supernatant was carefully taken, isopropanol was added, and the reaction was carried out at room temperature for 10 minutes. The RNA was centrifuged at 12,000 rpm for 10 minutes at 4 ° C, Abandoned. RNA was extracted from the RNA pellet by centrifugation (at 12,000 rpm for 5 min at 4 ° C) using 80% ethanol, air-dried, and DEPC H 2 O. After confirming the total RNA by electrophoresis, first strand cDNA was synthesized by quantifying RNA using a spectrophotometer.
그 다음, cDNA합성은 총 RNA (2 μg)에 0.5 μg oligo dT primer를 넣고 72℃에서 5분 동안 반응시킨 후 그 반응물 5 μL에 Reverse transcriptase mixture (5x RT buffer, 25 mM MgCl2, 2 mM dNTP, RNase Inhibitor, RTase)를 넣어 25℃에서 5분, 42℃에서 60분, 70℃에서 15분의 순서대로 반응 조건을 설정하여 cDNA를 합성하였다.Then, cDNA synthesis was performed by adding 0.5 μg oligo dT primer to total RNA (2 μg), reacting at 72 ° C for 5 minutes, adding a reverse transcriptase mixture (5x RT buffer, 25 mM MgCl 2 , 2 mM dNTP , RNase Inhibitor, RTase) was added and reaction conditions were set in the order of 5 minutes at 25 ° C, 60 minutes at 42 ° C, and 15 minutes at 70 ° C to synthesize cDNA.
그 후, 1 mg cDNA에 10 mM dNTPs, 10x Ex-TaqTM polymerase buffer, 2.5 U Ex-TaqTM DNA polymerase 와 하기와 같은 specific primer를 넣어 cDNA를 증폭시켰다. Target 유전자의 증폭을 위해 사용된 primer sequence는 다음과 같다. Then, put a specific primer as described below with 10 mM dNTPs, 10x Ex-Taq TM polymerase buffer, 2.5 U Ex-Taq TM DNA polymerase in 1 mg cDNA was amplified cDNA. The primer sequence used for the amplification of the target gene is as follows.
COX-2 유전자 COX-2 gene
Forward primer : 5'-AAG AAG AAA GTT CAT TCC TGA TCC C-3' (서열번호 1)Forward primer: 5'-AAG AAG AAA GTT CAT TCC TGA TCC C-3 '(SEQ ID NO: 1)
Reverse primer : 5'-TGA CTG TGG GAG GAT ACA TCT CTC C-3' (서열번호 2)
Reverse primer: 5'-TGA CTG TGG GAG GAT ACA TCT CTC C-3 '(SEQ ID NO: 2)
iNOS 유전자 iNOS gene
Forward primer : 5'-CTG CAG CAC TTG GAT CAG GAA CCT G-3' (서열번호 3)Forward primer: 5'-CTG CAG CAC TTG GAT CAG GAA CCT G-3 '(SEQ ID NO: 3)
Reverse primer : 5'-GGG AGT AGC CTG TGT GCA CCT GGA A-3' (서열번호 4)
Reverse primer: 5'-GGG AGT AGC CTG TGT GCA CCT GGA A-3 '(SEQ ID NO: 4)
GAPDH 유전자 GAPDH gene
Forward primer : 5'-CCG ATG CCC CCA TGT TTG TG-3'(서열번호 5)Forward primer: 5'-CCG ATG CCC CCA TGT TTG TG-3 '(SEQ ID NO: 5)
Reverse primer : 5'-GGC CAT GCC AGT GAG CTT CC-3' (서열번호 6)
Reverse primer: 5'-GGC CAT GCC AGT GAG CTT CC-3 '(SEQ ID NO: 6)
Cycling 조건은 먼저 95℃에서 2분 동안 반응시키는데 온도가 Tm (melting temperature) 값 이하로 떨어지면 프라이머 이량체(primer dimer) 형성이나 비특이적 시작이 일어나게 되므로, 이와 같은 난점을 극복하기 위하여 Hot start하였다. Three-step program (95℃ for 1 min, 55℃ for 1 min, and 72℃ for 1.5 min)을 30 cycles 반응시킨 후, 72℃에서 10분 동안 반응시킨 PCR 산물을 4℃에 보관하였다.The cycling condition is first reacted at 95 ° C for 2 minutes. When the temperature falls below the melting temperature (Tm), primer dimer formation or non-specific initiation occurs. The PCR products were incubated at 72 ° C for 10 min. The PCR products were stored at 4 ° C for 30 cycles of three-step program (95 ° C for 1 min, 55 ° C for 1 min, and 72 ° C for 1.5 min).
PCR 반응이 끝난 산물 10 μL를 0.2 mg/mL ethidium bromide가 들어있는 1 % 아가로스 겔에 전기영동 시켜 UV transilluminator로 증폭된 DNA 밴드를 AlphaDigiDoc 1200 software를 사용하여 스캔, 분석하였으며 발현 정도는 GAPDH gene에 대한 상대적인 양을 구하였다. 10 μL of the PCR product was electrophoresed on a 1% agarose gel containing 0.2 mg / mL ethidium bromide. The amplified DNA band was analyzed by
그 결과, 도 15에 나타난 바와 같이, 1 mg/mL의 LPS를 처리한 RAW 264.7 cell에서는 iNOS와 COX-2 유전자 발현의 정도가 negative control에 비하여 월등하게 증가하는 것을 볼 수 있었다. 그런데, 여기에 은행나무의 형성층 유래 줄기세포(CMCs)의 80% 에탄올 조추출물 50 μg/mL을 처리 시 iNOS와 COX-2 유전자 발현이 현저히 감소하여 iNOS의 경우는 LPS를 처리한 대조군에 비하여 57.1%, COX-2의 경우는 LPS 대조군에 비하여 83.4%가 감소하는 것을 알 수 있었다. As a result, as shown in Fig. 15, the degree of expression of iNOS and COX-2 gene was significantly increased in RAW 264.7 cell treated with 1 mg / mL of LPS compared to the negative control. However, the expression of iNOS and COX-2 gene was significantly decreased when 50 μg / mL of 80% ethanol extract of cambium stem cells (CMCs) from Ginkgo biloba was treated. As a result, iNOS was 57.1 %, And COX-2 was 83.4% less than the LPS control group.
또한, 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 분획 시료(50 μg/mL)를 처리하였을 경우 69%에서 100%의 iNOS 및 COX-2 유전자 발현이 저해됨을 알 수 있었다. 이러한 결과는 실시예 6-1의 도 14의 CMCs 추출 분획 시료의 NO 생성 억제에서 나타난 결과와 같이, 이들 시료가 항염증 효과를 가짐을 나타낸다.
In addition, it was found that 69% to 100% of iNOS and COX-2 gene expression was inhibited by treatment with cambium stem cells (CMCs) extract fraction (50 μg / mL). These results indicate that these samples have an anti-inflammatory effect, as shown by the inhibition of NO production in the CMCs extract fraction sample of Fig. 14 of Example 6-1.
6-3: 6-3: LPSLPS 의 of RAWRAW 264.7 264.7 macrophagemacrophage cellcell lineline 처리에 따른 Depending on the treatment MAPMAP kinasekinase activation에 대한 은행나무의 형성층 유래 줄기세포( activation of stem cells from cambium CMCsCMCs ) 추출물 분획 시료의 저해 효과) Inhibitory effect of extract fraction fractions
LPS를 macrophage cell에 처리하면 염증반응에 관여하는 다양한 mediator가 생산되는 것으로 알려져 있다. 이러한 mediator에는 염증성 cytokine도 포함되는데, 이를 위해서는 LPS에 의한 자극신호가 전달되어야 하며, 이 과정에서 MAP kinase activation이 중요한 단계로 여겨지고 있다. 따라서 LPS 처리에 의한 MAP kinase의 활성화가 CMCs 추출 분획 시료의 처리에 의하여 저해되는지 확인하였다.It is known that LPS is treated in macrophage cells to produce various mediators involved in the inflammatory reaction. These mediators also include inflammatory cytokines, which require signaling stimulation by LPS, and MAP kinase activation is considered to be an important step in this process. Therefore, activation of MAP kinase by LPS treatment was inhibited by CMCs And it was confirmed that it was inhibited by the treatment of the extracted fraction sample.
RAW 264.7 cell에 실시예 3의 각 분획시료와 실시예 2-1의 조추출물 (crude extract)를 50 μg/mL 농도로 먼저 처리한 다음 LPS를 1 μg/mL 농도로 처리하여 30분 배양하였으며, 이후 MAP kinase의 활성 억제 효과를 웨스턴 블라닝 (western blotting_을 이용하여 확인하였다. Each fraction sample of Example 3 and the crude extract of Example 2-1 were first treated at a concentration of 50 μg / mL in RAW 264.7 cells, treated with LPS at a concentration of 1 μg / mL and incubated for 30 minutes. The inhibitory effect of MAP kinase was confirmed by Western blotting.
즉, 상기에서 배양한 RAW 264.7 cell을 micro centrifuge tube에 수거하여 PBS를 넣어 세척한 다음, 용해 완충액(150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 2 mM EDTA, 1% NP-40, 10 mM VaF, 1 mM Na3VO4, 10 mM sodium pyrophosphate, 1 mM PMSF, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 0.1 mg/mL soybean inhibitor)으로 용해된 세포를 12,000 rpm에서 10분간 원심분리하여 상등액을 취하였다. BSA를 표준시료로 사용하여 각각의 단백질을 Bradford법으로 정량하였다. 단백질은 Laemmli sample buffer (0.625 M Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 2% SDS)로 녹여 20 μg의 lysate를 10% SDS-PAGE로 변성 분리하여, 젤을 0.45 mm hydrophobic PVDF (polyvinylidene difluoride) membrain (Hybond-P)에 전사시켰다. PVDF는 5% 탈지분유를 함유한 Tris buffered saline (TBS; 20 mM Tris/HCl, 137 mM NaCl, pH 7.6)으로 약 2시간 동안 blocking한 다음, 1차 항체(1:500)넣어 over night 반응한 후 TBS로 3회 세척하였다. 그 이후 HRP-conjugated anti-rabbit 2차 항체 용액(희석비율 1:1,000)으로 1시간 동안 상온에서 반응시켰으며, 상기와 동일하게 다시 세척한 후 enhanced chemiluminescence detection system western detection 용액을 사용하여 X-film에 감광시켰다. 각 단백질의 발현에 대한 대조군으로 β-actin에 대한 일차항체를 이용하여 위와 동일한 방법으로 수행하였다.The RAW 264.7 cells cultured in the above were collected in a micro centrifuge tube, washed with PBS, and then lysed in a solution buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 2 mM EDTA, 1% NP- Cells were lysed with 10 mM VaF, 1 mM Na3VO4, 10 mM sodium pyrophosphate, 1 mM PMSF, 10 mg / mL aprotinin, 10 mg / mL leupeptin and 0.1 mg / mL soybean inhibitor) Respectively. Each protein was quantitated by Bradford method using BSA as a standard sample. Proteins were dissolved in Laemmli sample buffer (0.625 M Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 2% SDS) and 20 μg of lysate was denatured by 10% SDS-PAGE. The gel was immersed in 0.45 mm hydrophobic PVDF difluoride) membrain (Hybond-P). PVDF was blocked with Tris buffered saline (TBS; 20 mM Tris / HCl, 137 mM NaCl, pH 7.6) containing 5% skimmed milk for about 2 hours and then over-reacted with primary antibody (1: 500) And then washed three times with TBS. Thereafter, the reaction was carried out at room temperature for 1 hour with a HRP-conjugated anti-rabbit secondary antibody solution (dilution ratio 1: 1,000). After washing the same again as described above, X- . As a control for the expression of each protein, the same method as above was carried out using the primary antibody against β-actin.
그 결과, 도 16에 나타난 바와 같이, RAW 264.7 macrophage cell line에서 1 μg/mL LPS의 처리에 의하여 ERK와 p38 MAP kinae의 activation이 현저히 증가함을 알 수 있었다. 그리고 50 μg/mL 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 시료의 처리시 ERK의 경우 27.4%, p38 MAP kinase의 경우 37.3%의 MAP kinase 활성화 저해 효과가 있음을 알 수 있었다. 은행나무의 형성층 유래 줄기세포(CMCs) 추출 분획시료의 처리에 의해서도 LPS에 의하여 유도된 MAP kinase 활성화가 저해됨을 알 수 있었는데, 특히 fraction #4의 경우 LPS 대조군 대비 50%의 활성화 저해효과가 있음을 알 수 있었다. 이는 상기 NO, iNOS, 그리고 COX-2 결과와 마찬가지로 CMCs 추출 분획 시료의 항염증 효과를 일관성 있게 입증하는 결과이다.
As a result, as shown in FIG. 16, activation of ERK and p38 MAP kinase was significantly increased by treatment with 1 μg / mL LPS in RAW 264.7 macrophage cell line. It was also found that 27.4% of ERK and 37.3% of p38 MAP kinase inhibited MAP kinase activation in the treatment of cambium stem cells (CMCs) extracted from 50 μg / mL of Ginkgo biloba. It was shown that MAPK activation induced by LPS was also inhibited by treatment of cambium stem cells derived from cambium stem cells (CMCs). Particularly,
6-4: 6-4: LPSLPS 의 of RAWRAW 264.7 264.7 macrophagemacrophage cellcell lineline 처리에 따른 Depending on the treatment NFNF -- kBkB activationactivation 에 대한 은행나무의 형성층 유래 줄기세포(Derived stem cells from gingko CMCsCMCs ) 추출물 분획 시료의 저해 효과) Inhibitory effect of extract fraction fractions
LPS를 macrophage cell에 처리하면 염증반응에 관여하는 다양한 mediator가 생산되며, 이러한 mediator인 염증성 cytokine의 생산을 위해서는 LPS에 의한 자극신호가 전달되어야 하며, 이 과정에서 MAP kinase activation이 중요한 중간단계이다. 그리고 MAP kinase 활성화에 의한 NF-kB activation이 유전자 발현의 마지막 결정 단계로 알려져 있다. 따라서 LPS 처리에 의한 IkB의 degradation과 이에 따른 NF-kB activation이 은행나무의 형성층 유래 줄기세포(CMCs) 추출 분획 시료의 처리에 의하여 저해되는지 확인하였다. Treatment of LPS with macrophage cells produces a variety of mediators that are involved in the inflammatory response. In order to produce inflammatory cytokines such as these mediators, LPS stimulation signals must be transmitted and MAP kinase activation is an important intermediate step in this process. Activation of NF-kB by activation of MAP kinase is known to be the final determinant of gene expression. Therefore, it was confirmed that the degradation of IkB by LPS treatment and the subsequent activation of NF-kB were inhibited by the treatment of cambium-derived stem cells (CMCs) extracted fraction.
RAW 264.7 cell에 실시예 3의 각 분획시료와 실시예 2-1의 조추출물 (crude extract)를 50 μg/mL 농도로 먼저 처리한 다음 LPS를 1 μg/mL 농도로 처리하여 1시간 배양하였으며, 이후 p-IkB와 NF-kB 활성 억제 효과를 웨스턴 블라팅을 이용하여 확인하였다.Each fraction sample of Example 3 and the crude extract of Example 2-1 were first treated at a concentration of 50 μg / mL in RAW 264.7 cells, treated with LPS at a concentration of 1 μg / mL and incubated for 1 hour. The inhibition of p-IkB and NF-kB activity was confirmed by Western blotting.
p-IkB의 실험방법은 실시예6-3과 동일하며, NF-kB는 NE-PER Nuclear & Cytoplasmic Extraction Reagents kit (Thermo science, Rockford, USA)를 사용하여 실험을 수행하였다. The experiment of p-IkB was the same as that of Example 6-3. NF-kB was performed using NE-PER Nuclear & Cytoplasmic Extraction Reagents kit (Thermo science, Rockford, USA).
상기에서 배양한 RAW 264.7 cell을 micro centrifuge tube에 수거하여 PBS를 넣어 세척(12,000 rpm for 5 min)한 다음, ice-cold Cytoplasmic extraction reagent I (CER I)용액을 넣어 15초간 vortex하여 cell을 풀어준 후 10분 동안 ice 상태를 유지시켰다. ice-cold Cytoplasmic extraction reagent II (CER II)용액 넣어 5초간 볼텍싱한 후 1분 동안 ice 상태를 유지하였다. 튜브를 5초간 볼텍싱한 다음 재빨리 4℃ micro-centrifuge에 옮겨 12,000 rpm에서 5분간 원심분리한 후 상등액(cytoplasmic extract)은 미리 차갑게 해 놓은 튜브에 옮겨 -80℃에 보관하였다.The RAW 264.7 cells cultured in the above were collected in a microcentrifuge tube, washed with PBS (12,000 rpm for 5 min), and then vortexed for 15 sec with ice-cold Cytoplasmic extraction reagent I (CER I) The ice condition was maintained for 10 minutes. The ice-cold Cytoplasmic extraction reagent II (CER II) solution was vortexed for 5 seconds and kept in ice for 1 minute. The tubes were vortexed for 5 seconds, then quickly transferred to a 4 ° C micro-centrifuge and centrifuged at 12,000 rpm for 5 minutes. The cytoplasmic extract was transferred to a pre-cooled tube and stored at -80 ° C.
남아있는 불용성 (pellet) 분획(fraction)은 ice-cold Nuclear Extraction Reagent (NER)을 넣어 15초간 강하게 vortex하여 ice 상태를 유지하는데 매 10분 간격으로 반복하여 강하게 볼텍싱해 준다(총 4회). 완전히 용해된 용액을 12,000 rpm에서 15분간 원심 분리하여 상등액(nuclear extract)을 미리 차갑게 해 놓은 튜브에 옮긴 후 다음 실험을 진행하였다. BSA를 표준시료로 사용하여 각각의 단백질을 Bradford법으로 정량하였다. 단백질은 Laemmli sample buffer (0.625 M Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 2% SDS)로 녹여 20 μg의 lysate를 10% SDS-PAGE로 변성 분리하여, 젤을 0.45 mm hydrohhobic PVDF (polyvinylidene difluoride) membrain (Hybond-P)에 전이시켰다. PVDF는 5% 탈지분유를 함유한 Tris buffered saline (TBS; 20 mM Tris/HCl, 137 mM NaCl, pH 7.6)으로 약 2시간 동안 차단시킨 다음, 1차 항체(1:500)넣어 over night 반응한 후 TBS로 3회 세척하였다. 그 이후 HRP-conjugated anti-rabbit 2차 항체 용액(희석비율 1:1,000)으로 1시간 동안 상온에서 반응시켰으며, 상기와 동일하게 다시 세척한 후 enhanced chemiluminescence detection system western detection 용액을 사용하여 X-film에 감광시켰다. 각 단백질의 발현에 대한 대조군으로 β-actin에 대한 일차항체를 이용하여 위와 동일한 방법으로 수행하였다.The remaining pellet fraction is vortexed vigorously for 15 seconds with ice-cold Nuclear Extraction Reagent (NER) and vortexed vigorously vigorously vigorously at intervals of 10 minutes (4 total). The completely dissolved solution was centrifuged at 12,000 rpm for 15 minutes and the nuclear extract was transferred to a pre-cooled tube and the following experiment was carried out. Each protein was quantitated by Bradford method using BSA as a standard sample. Proteins were dissolved in Laemmli sample buffer (0.625 M Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 2% SDS) to remove 20 μg of lysate by 10% SDS-PAGE. The gels were resuspended in 0.45 mM hydrohhobic PVDF difluoride) membrain (Hybond-P). PVDF was blocked with Tris buffered saline (TBS; 20 mM Tris / HCl, 137 mM NaCl, pH 7.6) containing 5% skim milk for about 2 hours and then over-reacted with primary antibody (1: 500) And then washed three times with TBS. Thereafter, the reaction was carried out at room temperature for 1 hour with a HRP-conjugated anti-rabbit secondary antibody solution (dilution ratio 1: 1,000). After washing the same again as described above, X- . As a control for the expression of each protein, the same method as above was carried out using the primary antibody against β-actin.
그 결과, 도 17에 나타난 바와 같이, 1 μg/mL LPS의 처리에 의하여 RAW 264.7 macrophage cell line에서 IkB의 phosphorylation에 의한 degradation과 NF-kB activation이 현저히 증가함을 알 수 있었다. 그리고 50 μg/mL 은행나무의 형성층 유래 줄기세포(CMCs) 추출 시료의 처리 시 NF-kB activation이 10.7% 정도 저해됨을 알 수 있었다. 흥미롭게 은행나무의 형성층 유래 줄기세포(CMCs) 추출 시료 분획의 처리에 의해서는 LPS에 의하여 유도된 NF-kB activation이 매우 현격하게 저해됨을 알 수 있었는데, 그 저해 정도가 약 70%에 이르는 것을 알 수 있었다. 이는 상기 NO, iNOS, COX-2, 그리고 MAP kinase 활성화 저해 결과와 마찬가지로 CMCs 추출 분획 시료의 항염증 효과를 일관성 있게 입증하는 결과이다.
As a result, as shown in FIG. 17, the treatment with 1 μg / mL of LPS significantly increased the degradation by IkB phosphorylation and NF-kB activation in the RAW 264.7 macrophage cell line. In addition, NF-kB activation was inhibited by 10.7% when treated with 50 μg / mL gambia stem cells derived from cambium-derived stem cells (CMCs). Interestingly, it was found that treatment of the cambium stem cells (CMCs) derived from the cambium extract significantly inhibited the activation of NF-kB induced by LPS. The degree of inhibition was about 70% there was. This is consistent with the results of inhibition of NO, iNOS, COX-2, and MAP kinase activation.
6-5: 6-5: LPSLPS 의 of RAWRAW 264.7 264.7 macrophagemacrophage cellcell lineline 처리에 따른 염증성 Inflammation due to treatment cytokinecytokine 발현에 대한 은행나무의 형성층 유래 줄기세포( Expression of cambium stem cells from cambium CMCsCMCs )) 추출물 분획 시료의 저해 효과Inhibitory effect of extract fraction
LPS를 macrophage cell에 처리하면 염증반응에 관여하는 다양한 mediator가 생산되는데, 가장 중요한 factor가 염증성 cytokine의 생산이다. 이에 가장 중요한 염증성 cytokine인 IL-6와 TNF-a의 LPS 자극에 의한 생산이 은행나무의 형성층 유래 줄기세포(CMCs) 추출 분획 시료의 처리에 의하여 저해되는지 확인하였다. Treatment of LPS with macrophage cells produces a variety of mediators that are involved in the inflammatory response. The most important factor is the production of inflammatory cytokines. We confirmed that the production of IL-6 and TNF-a, the most important inflammatory cytokines, by LPS stimulation was inhibited by treatment of cambium stem cells (CMCs) extracted fraction.
은행나무의 형성층 유래 줄기세포(CMCs) 추출 분획 시료의 염증성 사이토카인 생성억제효과를 조사하기 위하여 RAW 264.7 cell에 실시예 3의 각 분획시료와 실시예 2-1의 조추출물 (crude extract)를 50 μg/mL 농도로 먼저 처리한 다음 LPS를 1 μg/mL 농도로 처리하여 48시간 배양한 세포배양액을 사용하여 ELISA 방법으로 측정하였다.In order to investigate the inhibitory effect of CMCs extracted from cambium stem cells on inflammatory cytokine production, each fraction sample of Example 3 and a crude extract of Example 2-1 were dissolved in RAW 264.7 cell in a concentration of 50 μg / mL, followed by treatment with LPS at a concentration of 1 μg / mL for 48 h. Cell culture was then measured by ELISA.
먼저 각 사이토카인의 capture antibody를 96-well ELISA plate에 넣고 4℃에서 하룻밤 반응시켰다. Plate를 0.05% Tween-20이 포함된 1xPBS (PBS-T)로 5회 세척한 다음 2% BSA가 포함된 1x assay diluent 용액으로 실온에서 2시간 blocking하였다. Plate를 1x PBS-T로 3회 세척한 다음, 세포 배양액 또는 각 사이토카인 표준단백질을 넣어 2시간 동안 실온에서 반응시켰다. 이를 다시 1x PBS-T로 5회 세척하고 detection antibody를 넣어 실온에서 2시간 반응시켰다. Plate를 다시 1x PBS-T로 5회 세척하고 avidin-HRP 용액을 넣어 실온에서 30분간 반응시켰다. 이를 1x PBS-T용액으로 7회 세척한 다음 TMB 기질용액을 넣고 최종 15분간 실온에서 반응시키고 , 반응정지액(1 M H3PO4)을 첨가하여 반응을 정지 시켰다. Plate의 반응 정도를 microplate reader에서 430 nm 흡광도로 측정하였다. First, each cytokine capture antibody was added to a 96-well ELISA plate and reacted overnight at 4 ° C. Plate was washed 5 times with 1x PBS (PBS-T) containing 0.05% Tween-20 and then blocked with 1x assay diluent solution containing 2% BSA for 2 hours at room temperature. The plate was washed three times with 1x PBS-T, and the cell culture medium or each cytokine standard protein was added thereto, followed by reaction at room temperature for 2 hours. The cells were washed 5 times with 1x PBS-T and incubated for 2 hours at room temperature. The plate was washed 5 times with 1x PBS-T, and the avidin-HRP solution was added and reacted at room temperature for 30 minutes. After washing with 1 × PBS-T solution for 7 times, TMB substrate solution was added and the reaction was allowed to proceed for 15 minutes at room temperature. The reaction was terminated by adding a stop solution (1 MH 3 PO 4 ). Plate reactivity was measured by absorbance at 430 nm in a microplate reader.
그 결과, 도 18에 나타난 바와 같이, RAW 264.7 cell에 은행나무의 형성층 유래 줄기세포(CMCs) 에탄올 추출물과 시료를 각각 50 μg/mL농도로 처리한 다음 LPS 1 μg/mL을 첨가하여 48시간 배양한 후 배양액에 존재하는 IL-6와 TNF-a 농도를 확인한 결과, 예상한 바와 같이 LPS 만 처리한 군보다 은행나무의 형성층 유래 줄기세포(CMCs) 시료를 처리한 군 모두에서 IL-6와 TNF-a의 발현이 유의한 정도로 감소됨을 알 수 있었다.As a result, RAW 264.7 cells were treated with 50 μg / mL of the ethanol extract of cambium stem cells derived from cambium (CMCs) and a sample, respectively, and then 1 μg / mL of LPS was added thereto. As expected, the levels of IL-6 and TNF-a in the culture medium were higher than those in the LPS-treated group, -a expression was significantly decreased.
이러한 결과로 미루어 은행나무의 형성층 유래 줄기세포(CMCs) 추출물에서 마련된 분획 추출물을 LPS로 자극된 RAW 264.7 macrophage cell을 이용한 in vitro 항염증 효과 실험 결과 매우 우수한 항염증 효과를 보유함을 알 수 있었다.
Using these results in a deferred cost a fraction extract prepared from the cambium-derived stem cells (CMCs) an extract of Ginkgo LPS-stimulated RAW 264.7 macrophage cell In vitro antiinflammatory effect test showed that it has very good antiinflammatory effect.
은행나무의 형성층 유래 줄기세포 추출물의 Stem cell extracts from cambium-derived cambium inin vitrovitro 항산화 효과 측정 Antioxidant effect measurement
실시예 4에서 은행나무의 형성층 유래 줄기세포 추출물 분획의 항산화 활성을 측정하였던 것에 추가하여, 다음과 같이 은행나무의 형성층 유래 줄기세포 추출물 자체의 항산화 활성을 Xanthin/xanthin oxidase assay와 deoxyribose assay를 시행하여 확인하였다.
In addition to measuring the antioxidant activity of the cambium stem cell extract fraction in Example 4, the antioxidant activity of cambium stem cells derived from cambium was evaluated by Xanthin / xanthin oxidase assay and deoxyribose assay Respectively.
7-1: 7-1: XanthinXanthin // xanthinxanthin oxidaseoxidase 저해활성 효과 분석 Analysis of inhibitory activity effect
Xanthin/xanthin oxidase 시스템은 활성산소에 의한 산화스트레스 연구에서 O.-와 HO를 생성하기 위해 널리 이용되어왔다. Xanthin/Xanthin oxidase는 박테리아에서 인간에 이르기까지 널리 분포하고 있으며 molybdenum iron-sulfur flavin hydroxylase로 알려진 효소들 중의 하나이다. 또한 Xanthin oxidase는 생체 내 purine 대사에 관여하는 효소로써 xanthin 또는 hypoxanthin에서 요산을 형성하여 통풍을 일으키는 효소로 요산이 과도하게 생성되어 혈액 내에 증가하면 관절이나 관절주위조직 및 신장 등에 침착되어 염증을 일으키고, 이로 인하여 통증 및 신장 질환을 일으킨다. Xanthin/Xanthin oxidase는 hypoxanthine을 산화시켜 xanthine으로 전환시키고, 이것을 다시 uric acid로 산화시키는데 이 과정에서 O2 -와 H2O2가 생성 된다. X/XO 시스템은 in vitro 실험에서 O. 2 -와 H2O2에 대한 chemical probe들과 함께 사용되어 활성산소에 의한 세포수준 이하에서의 손상이나 그에 대한 방어기작(특히, 효소적 방어)의 활성을 측정하기 위해 이용될 수 있다. Xanthin / xanthin oxidase system have been widely used to generate the O .- and HO in the study of oxidative stress caused by free radicals. Xanthin / Xanthin oxidase is widely distributed from bacteria to humans and is one of the enzymes known as molybdenum iron-sulfur flavin hydroxylase. Xanthin oxidase is an enzyme involved in the in vivo purine metabolism. It forms uric acid in xanthin or hypoxanthin and causes gout. As the uric acid is excessively produced in the blood, it is deposited in joints, joint tissues and kidneys to cause inflammation, This causes pain and kidney disease. Xanthin / Xanthin oxidase oxidizes hypoxanthine to xanthine, which is then oxidized to uric acid, which produces O 2 - and H 2 O 2 . X / XO system in vitro In experiments O. 2 - and H 2 O 2 can be used to measure the activity of damage below the cellular level by reactive oxygen species or its defense mechanism (especially enzymatic defense).
Xanthin oxidase 저해활성을 측정하기 위하여, 실시예 2-1의 에탄올 추출물에 reaction mixture (30 mM EDTA (pH 7.4), 30 mM xanthine, 1.42 mM NBT(nitro blue tetrazolium))와 50 mM PBS를 넣어준 후 xanthine oxidase (0.5 U/mL)를 첨가하여, 15분 동안 반응시켰다. 그리고 용액의 흡광도를 560 nm에서 측정하여 시료가 어느 정도의 항산화 효과를 가지는지 그 저해 정도를 대조군과 비교하여 측정하였다. 대조군으로는 항산화제를 넣지 않고 xanthine oxidase만을 처리하였을 때 반응의 결과 나타나는 흡광도를 측정하여 결정하였으며, 각 분획 시료의 superoxide radical scavenging를 백분율로 환산하여 결정하였다.To determine Xanthin oxidase inhibitory activity, the reaction mixture (30 mM EDTA (pH 7.4), 30 mM xanthine, 1.42 mM NBT (nitro blue tetrazolium)) and 50 mM PBS were added to the ethanol extract of Example 2-1 xanthine oxidase (0.5 U / mL) was added and reacted for 15 minutes. The absorbance of the solution was measured at 560 nm and the degree of inhibition of the antioxidative effect of the sample was measured in comparison with the control. As a control, the absorbance of xanthine oxidase treated without antioxidant treatment was determined by measuring absorbance, and the superoxide radical scavenging of each fraction was converted into a percentage.
10
50
100
500One
10
50
100
500
30.95
53.97
73.8
85.7227.78
30.95
53.97
73.8
85.72
42.86
55.24
63.18
56.5835.4
42.86
55.24
63.18
56.58
7-2: 7-2: DeoxyriboseDeoxyribose assayassay
먼저 Non site-specific hydroxyl radical formation assay을 수행하였다. 즉, 유리 tube안에 100 μM FeCl3, 104 μM EDTA (pH 7.4)를 넣어 10분 동안 반응시킨 다음 1.5 mM 과산화수소, 2.5 mM Deoxyribose, 100 μM vitamin C를 넣어준 후 실시예 2-1의 은행나무의 형성층 유래 줄기세포(CMCs) 에탄올 추출물을 넣어 37℃에서 1시간 동안 반응시켰다. 각각의 반응시료에 1.5% 2-TBA (2-thiobarbituric acid)와 2.8% TCA (trichloroacetic acid)를 넣어 잘 혼합한 다음 80℃에서 30분 동안 반응시킨 후 532 nm에서 흡광도를 측정하였다.
First, non-site-specific hydroxyl radical formation assays were performed. That is, 100 μM FeCl 3 and 104 μM EDTA (pH 7.4) were placed in a glass tube and reacted for 10 minutes. Then, 1.5 mM hydrogen peroxide, 2.5 mM Deoxyribose and 100 μM vitamin C were added thereto. The cambium-derived stem cell (CMCs) ethanol extract was added and reacted at 37 ° C for 1 hour. Each reaction sample was mixed well with 1.5% 2-TBA (2-thiobarbituric acid) and 2.8% TCA (trichloroacetic acid), reacted at 80 ° C for 30 minutes and absorbance was measured at 532 nm.
그 다음, Site-specific hydroxyl radical formation assay은 다음과 같이 수행하였다. 모든 과정의 실험이 상기 non site-specific hydroxyl radical formation assay와 동일하나, vitamin C 대신에 같은 용량의 phosphate buffer를 넣어 실험하였다. The site-specific hydroxyl radical formation assay was then performed as follows. All the procedures were the same as the non-site-specific hydroxyl radical formation assays described above except that instead of vitamin C, the same amount of phosphate buffer was added.
Sugar인 2-deoxyribose에 대한 OH.의 반응은 많은 산물들을 발생시킨다. Fenton system (Fe3 +-ascorbate-EDTA-H2O2)으로 발생하는 hydroxyl radical 에 의해 deoxyribose는 분해되며, 그 부산물이 산성 상태(낮은 pH)에서 가열에 의해 malonaldehyde (MDA)가 생성되게 된다. 생성된 malonaldehyde는 thiobarbituric acid (TBA) 와 반응하여 핑크색의 chromogen (2TBA-MDA)을 형성함으로써 532 nm에서 최대의 흡광도를 나타낸다. 따라서 시료 내 hydroxyl radical 소거활성이 존재하는 경우 시료 첨가에 의해 deoxyribose의 분해가 억제되며 흡광도가 감소하게 된다. 이러한 원리를 이용하여 ascorbic acid, H2O2, Fe(III)-EDTA, 2-deoxyribose가 함께 존재하는 모델시스템에서 여러 OH. scavengers들의 rate constant를 측정 비교할 수 있으나, 그 scavenger들과 이들 구성물들과의 반응이 없어야 한다는 조건이 부과된다. 시료의 hydroxyl radical 소거활성은 시료 무첨가군의 흡광도 변화를 100%로 기준하여 시료 첨가군의 흡광도 변화를 hydroxyl radical 생성 억제율로 표시하였다(표 9). OH for 2-deoxyribose, a sugar . The reaction of the compound produces many products. Deoxyribose is decomposed by hydroxyl radicals generated by Fenton system (Fe 3 + -ascorbate-EDTA-H 2 O 2 ) and malonaldehyde (MDA) is produced by heating at the acid state (low pH). The resulting malonaldehyde reacts with thiobarbituric acid (TBA) to form a pink chromogen (2TBA-MDA), which shows the maximum absorbance at 532 nm. Therefore, in the presence of hydroxyl radical scavenging activity in the sample, decomposition of deoxyribose is inhibited by the addition of the sample and the absorbance decreases. In this model system, the presence of ascorbic acid, H 2 O 2 , Fe (III) -EDTA, and 2-deoxyribose coexist . The rate constant of the scavengers can be measured and compared, but the condition is imposed that there should be no reaction between these scavengers and these constituents. The hydroxyl radical scavenging activity of the samples was expressed as the percent inhibition of hydroxyl radical formation by changing the absorbance of the sample-added group based on the absorbance change of 100% of the sample-free addition group (Table 9).
은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 농도가 높아질수록 non site specific (hydroxyl radical)의 효과보다 site-specific 즉 2가 금속이온의 scavenger 효과가 농도 비례 상승하는 것으로 나타났다. As the concentration of cambium stem cell (CMCs) extract increased, the site-specific, ie, scavenger effect of divalent metal ion was increased in proportion to the concentration of non-site specific (hydroxyl radical).
(mg/mL)CMCs concentration
(mg / mL)
(% inhibition)Site-specific
(% inhibition)
(% inhibition)Non site-specific
(% inhibition)
1
10
50Control
One
10
50
4.00±0.05
54.28±0.08
93.14±0.120.00
4.00 ± 0.05
54.28 ± 0.08
93.14 + 0.12
13.00±0.06
19.19±0.11
44.12±0.100.00
13.00 + 0.06
19.19 ± 0.11
44.12 + - 0.10
은행나무의 형성층 유래 줄기세포(Stem cells derived from cambium CMCsCMCs ) 추출물의 ) Of the extract inin vivovivo 항산화 효과 Antioxidative effect
실시예 7의 은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 결과에 근거하여 in vivo 항산 효과 실험을 하기 위해 다음과 같이, 대표적 항산화 물질인 vitamin C와 비교 실험하였다.Based on the results of cambial stem cell-derived stem cells (CMCs) extract of Example 7, in In order to test vivo antioxidant effect, vitamin C, a representative antioxidant, was tested as follows.
간은 영양소 및 물질 대사와 해독을 담당하는 중요한 장기로 각종 스트레스와 체내 독성 물질로 인하여 실험동물 및 인간의 간 손상을 유발시키는바, 혈액과 간 조직에서 은행나무의 형성층 유래 줄기세포(CMCs) 추출물 시료의 활성산소 소거 효과와 과산화물 생성 억제 실험을 하였다. Mouse의 혈청과 간 조직을 이용하여 간 기능의 효소 활성, 항산화 효소 활성 등의 실험적 접근을 통한 생리 기능적 효과를 실험함으로써 은행나무의 형성층 유래 줄기세포 추출물의 항산효과를 입증하고자 하였다.
The liver is an important organs responsible for nutrients and metabolism and detoxification. It induces liver damage in experimental animals and humans due to various stresses and toxins in the body. As a result, stem cells (CMCs) The effect of scavenging of free radicals and the inhibition of peroxide formation were studied. We tried to demonstrate the antioxidant effect of the cambium stem cell extracts from the ginkgo using experimental and experimental approaches such as enzymatic activity of liver function and antioxidant enzyme activity using mouse serum and liver tissue.
8-1: 실험동물 사육 및 8-1: Experimental animal breeding and 실험군Experimental group
은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 in vivo 항산화 효과를 위한 실험동물은 4주령의 암컷 ICR mouse 18마리를 오리엔트사(대전, 대한민국)로부터 구입하였다. 실험동물은 일정한 조건(온도: 21±2℃, 습도: 50~60%, 명암: 12시간 주기(07:00~19:00))하의 사육실에서 일반 고형사료와 물을 무제한 공급하면서 1주 동안 적응시킨 후 실험에 사용하였다. ICR mouse 6마리를 1군으로 하여 Normal control군과 은행나무의 형성층 유래 줄기세포(CMCs) 군, Vitamin C군 등의 실험군으로 구분하였다. Normal control군은 증류수 0.5 mL를 3주 동안 구강투여 하였으며, 실험군은 실시예 2-1의 은행나무의 형성층 유래 줄기세포(CMCs) 에탄올 추출물 또는 vitamin C를 3일에 1번 200 mg/kg의 농도로 증류수에 녹여 0.5 mL씩 3주 동안 구강투여 하였다.
The cambium-derived stem cells (CMCs) in the extract of Ginkgo biloba For the vivo antioxidant effect, 18 female ICR mice of 4 weeks old were purchased from Orient (Daejeon, Korea). Experimental animals were maintained in feeder room under constant conditions (temperature: 21 ± 2 ℃, humidity: 50-60%, darkness: 12 hour period (07: 00 ~ 19: 00) After adaptation, it was used in the experiment. Six ICR mice were divided into three groups: normal control group, cambium stem cells (CMCs), and Vitamin C group. In the normal control group, 0.5 mL of distilled water was orally administered for 3 weeks. In the experimental group, the ethanol extract of cambium-derived stem cells (CMCs) or vitamin C from the cambium of Example 2-1 was administered at a concentration of 200 mg / kg once every three days Dissolved in distilled water, and administered orally in 0.5 mL increments for 3 weeks.
8-2: 시료 채취8-2: Sampling
실험 시작 12시간 전에 절식시킨 mouse를 경추탈구 시키기 전에 먼저 혈청을 얻기 위하여 mouse 안와정맥에서 혈액을 채취하여 30분간 실온에서 방치, 혈액을 응고시켰다. 응고된 혈액을 4℃에서 3,000 rpm으로 15분간 원심분리하여 얻은 상등액(혈청)을 수거하여 -80℃ 초저온 냉동고에 보관하였다. 혈액을 채취한 mouse는 경추탈구 시킨 후 간 조직을 적출하여 차가운 생리식염수로 세척한 다음 간 조직을 세절하고 3회 수세하여 혈액을 제거한 후 조직 0.5 g을 취하여 각 조직을 homogenize tube에 넣고 5배량의 potassium phosphate buffer (pH 7.3)를 넣은 후 homogenizer로 5분간 균질화시켰다. 이 균질액을 4℃에서 원심분리(20,000 xg, 20분)하여 상등액을 취하여 시료로 사용하였다.Before the disruption of the cervical vertebrae, 12 hours before the start of the experiment, blood was collected from the orbit of the mouse to obtain serum, and the blood was allowed to stand for 30 minutes at room temperature. The supernatant (serum) obtained by centrifuging the coagulated blood at 3,000 rpm for 15 minutes at 4 ° C was collected and stored at -80 ° C in a cryogenic freezer. After removing the liver from the cervical dislocation, the mice were washed with cold physiological saline, and the liver tissues were sieved and washed three times to remove the blood. 0.5 g of tissue was taken and each tissue was placed in a homogenize tube. Potassium phosphate buffer (pH 7.3) was added and homogenized with a homogenizer for 5 minutes. This homogenate was centrifuged (20,000 x g , 20 minutes) at 4 ° C and the supernatant was taken and used as a sample.
8-3: 간 조직을 이용한 은행나무의 형성층 유래 줄기세포(8-3: Stem cells derived from cambium of cambium using liver tissue CMCsCMCs ) 추출물의 항산화 활성 분석) Antioxidant Activity Analysis of Extracts
은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 in vivo 항산화 효과 분석을 위한 기초 연구로서 실시예 8-2에서 채취한 간 조직으로 항산화효소인 GSH concentration, SOD activity, Catalase activity, GPx activity를 측정하였다.The cambium-derived stem cells (CMCs) in the extract of Ginkgo biloba The antioxidant enzyme GSH concentration, SOD activity, catalase activity, and GPx activity were measured in the liver tissue collected in Example 8-2 as a basic study for the vivo antioxidant effect analysis.
과산화가 유발된 지질은 GSH와 thiols 함유 단백질과 상호작용을 하며, 이러한 상호작용을 통해 산화적 스트레스 유발 시 GSH 감소와 thiols 함유 단백질의 불활성화를 가져온다. 세포내 대부분의 주요 효소가 활성화되기 위해 필요한 thiols에 산화가 유발되면 효소의 활성이 파괴된다. 이러한 산화적 불활성화에 의해 세포사가 유발되게 되는데 생체 내 활성산소 소거제로 알려진 GSH는 GPx에 의해 과산화수소를 제거하면서 GSSH로 전환되고, GSSH는 gluthathion reductase (GR)에 의해 NADPH를 소모하면서 다시 GSH로 환원되어 활성산소로부터 세포를 보호하는데 중요한 역할을 한다. 이에 GSH 양에 대한 은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 영향을 알아보기 위해 Biovision사의 gluthathion concentration assay kit를 사용하여 간 조직에서 GSH 양의 변화를 측정하여 확인하였다. Lipid induced lipid peroxidation interacts with GSH and thiols - containing proteins, and this interaction leads to oxidative stress - induced reduction of GSH and inactivation of thiols - containing proteins. Most of the major enzymes in the cell are oxidized to the thiols needed for activation, which destroys the activity of the enzyme. GSH, which is known as a reactive oxygen scavenger in vivo, is converted to GSSH by removing hydrogen peroxide by GPx and GSSH is reduced to GSH by consuming NADPH by gluthathion reductase (GR) And plays an important role in protecting cells from active oxygen. To investigate the effect of cambium stem cells (CMCs) extracted from ginkgo biloba on the amount of GSH, we measured changes in GSH levels in liver tissues using a gluthathion concentration assay kit from Biovision.
그 결과, 표 10 및 도 19A에 나타난 바와 같이, 은행나무의 형성층 유래 줄기세포(CMCs) 군, Vitamin C군의 GSH 함량이 Normal control군에 비하여 유의적으로 높게 나타난 것을 확인할 수 있었다. 이는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 생체 내 활성산소를 소거하는 효과가 있음을 입증하는 결과이다.
As a result, as shown in Table 10 and FIG. 19A, it was confirmed that GSH content of cambium stem cells derived from cambium-derived stem cells (CMCs) and Vitamin C was significantly higher than that of normal control group. This is the result of proving that cambium stem cell (CMCs) extracts from cambium have the effect of eliminating active oxygen in vivo.
한편, 세포내 SOD (superoxide dismutase)는 산소유리기의 세포손상에 대한 1차 방어선으로 산화과정에서 생성된 superoxide anion을 과산화수소로 전환시키고 과산화물을 신속히 분해시켜 활성산소로부터 세포를 보호한다. 활성산소를 제일 처음 제거시키는 효소로 활성산소와 관련된 질병을 예방하거나 치료하는 역할을 수행한다. 이에 SOD 활성에 대한 은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 영향을 알아보기 위해 간 조직에서 SOD 효소의 활성도 변화를 Cayman Chemical Company의 Superoxide dismutase assay kit를 사용하여 간 조직에서 SOD 활성을 측정하여 확인하였다.On the other hand, intracellular SOD (superoxide dismutase) is the first line of defense against the cell damage of oxygen free radicals. It converts superoxide anion generated in the oxidation process into hydrogen peroxide and rapidly decomposes the peroxide to protect cells from free radicals. It is the first enzyme that removes active oxygen, and acts to prevent or treat diseases related to active oxygen. To investigate the effect of cambium stem cells (CMCs) extracts on the activity of SOD, the activity of SOD enzyme in liver was measured by SOD activity in hepatic tissue using Superoxide dismutase assay kit of Cayman Chemical Company Respectively.
그 결과, 표 10 및 도 19B에 나타난 바와 같이, 은행나무의 형성층 유래 줄기세포(CMCs) 군, Vitamin C군이 Normal control군에 비하여 유의적으로 활성이 높게 나타난 것을 확인할 수 있었다. 이는 상기 GSH 함량의 결과와 마찬가지로 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 생체 내 활성산소를 소거하는 효과가 있음을 입증하는 결과이다.
As a result, as shown in Table 10 and FIG. 19B, it was confirmed that the cambium-derived stem cell (CMCs) group and Vitamin C group were significantly more active than the normal control group. As a result of the above GSH contents, it is a result of proving that cambium stem cells derived from cambium-derived stem cells (CMCs) have the effect of eliminating active oxygen in vivo.
아울러, Catalase는 hemoprotein으로서 한 분자당 3가 철이온(Fe+++)이 4개가 있으며 효소 활성 시에는 산화 상태로 존재한다. SOD가 활성산소를 제거하면 과산화수소가 생기는데 이 과산화수소는 호기성 당 분해 산화과정의 최종산물로서 세포 독성 작용이 있으므로 세포 내에 축적되면 세포가 죽게 된다. 이 과산화수소를 가수분해하여 1차적으로 활성산소를 제거하여 방어하는 효소가 바로 이 catalase이다. 따라서, Catalase활성에 대한 은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 영향을 알아보기 위해 간 조직에서 catalase 효소의 활성도 변화를 Invitrogen사의 Amplex Red catalase assay kit를 사용하여 간 조직에서 catalase 활성을 측정하여 확인하였다.In addition, Catalase is a hemoprotein with four trivalent iron ions (Fe +++) per molecule and is present in an oxidized state during enzyme activation. When SOD removes active oxygen, hydrogen peroxide is generated. This hydrogen peroxide is the final product of the aerobic glycolysis and oxidation process. This enzyme catalyzes the hydrolysis of hydrogen peroxide to remove reactive oxygen species first. To investigate the effects of cambium stem cells (CMCs) extracts on catalase activity, catalase activity in liver tissues was measured by using Invitrogen's Amplex Red catalase assay kit Respectively.
그 결과, 표 10 및 도 19C에 나타난 바와 같이, Normal control군에 비하여 vitamin C군, 은행나무의 형성층 유래 줄기세포(CMCs)군 모두 투여에 따른 변화가 관찰되지 않았다. 항산화물질에 따라 SOD가 활성산소를 제거하면 catalase와 GPx효소 모두 작용하는 물질, GPx효소만 작용하는 물질, catalase효소만 작용하는 물질 등이 있다고 하는데, vitamin C와 CMCs는 GPx 경로를 거쳐 과산화수소를 제거해주는 물질로 보여진다.
As a result, as shown in Table 10 and FIG. 19C, there was no change in administration of vitamin C group and cambium stem cells derived from cambium-derived stem cells (CMCs) compared to the normal control group. According to antioxidants, when SOD removes active oxygen, there are substances that act on both catalase and GPx enzyme, GPx enzyme only, and catalase enzyme only. Vitamin C and CMCs pass through GPx pathway and remove hydrogen peroxide It is seen as a substance to give.
한편, SOD가 활성산소에 의해 생성된 과잉의 과산화수소는 체내 catalase와 GPx (gluthathion peroxidase)활성에 의해 물로 무독화 되는데 catalase활성은 과산화수소의 1차적 방어효소인 반면, GPx는 제거되지 못한 과산화수소를 제거하는 일종의 활성산소 잔해를 말끔히 제거하여 주는 효소가 바로 이 gluthathion peroxidase이다. 즉 언제든지 활성산소가 될 가능성을 지니고 있는 과산화수소를 제거해주는 주된 역할을 하는 물질이다. 또한 GPx는 손상된 세포를 원래 상태로 수리하고 복구하는 역할도 한다. 따라서, GPx활성에 대한 은행나무의 형성층 유래 줄기세포(CMCs) 추출물의 영향을 알아보기 위해 간 조직에서 GPx 효소의 활성도 변화를 Cayman Chemical Company의 gluthathion peroxidase assay kit를 사용하여 간 조직에서 GPx 효소 활성을 측정하여 확인하였다.On the other hand, the excess hydrogen peroxide produced by SOD by reactive oxygen species is detoxified by the catalase and GPx (gluthathion peroxidase) activity in the body, whereas the catalase activity is the primary protective enzyme of hydrogen peroxide, while the GPx removes hydrogen peroxide This gluthathion peroxidase is an enzyme that clears away some sort of active oxygen debris. That is, it is a substance that plays a major role in removing hydrogen peroxide that has the potential to become active oxygen at any time. GPx also serves to repair and repair damaged cells in their original state. To investigate the effect of cambium stem cells (CMCs) extracts on GPx activity, the activity of GPx enzymes in liver tissues was measured using the gluthathion peroxidase assay kit from Cayman Chemical Company. Respectively.
그 결과, 표 10 및 도 19D에 나타난 바와 같이, 은행나무의 형성층 유래 줄기세포(CMCs)군, Vitamin C군이 Normal control군에 비하여 유의적으로 높게 나타난 것을 확인할 수 있었다. 이는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 생체 내 과산화수소를 제거하는 효과가 있음을 입증하는 결과이다.
As a result, as shown in Table 10 and FIG. 19D, it was confirmed that stem cells of cambium-derived stem cells (CMCs) and vitamin C group were significantly higher than normal control group. This is the result of proving that the cambium stem cell (CMCs) extract from the cambium has the effect of removing hydrogen peroxide in vivo.
8-4: 8-4: MouseMouse 혈청을 이용한 은행나무 Ginkgo biloba using serum CMCsCMCs 추출물의 생화학적 효소활성 분석 Biochemical enzyme activity analysis of extract
실시예 8-2의 Mouse에서 채취한 혈청을 녹십자에 의뢰하여 간 기능의 혈액학적 간 지표물질인 ALT, AST, ALP, LDH를 측정하였다. 그 결과는 표 11 및 도 20과 같다. Serum from the mouse of Example 8-2 was assigned to Green Cross to measure the liver hematological indexes ALT, AST, ALP and LDH. The results are shown in Table 11 and FIG.
ALT (alanine aminotransferase)는 심장근과 간세포 내에 있는 특성효소로서 조직세포의 손상에 의해 혈청중의 활성도가 증가되어지는데, 특히 만성간염의 경우 현저하게 증가된다. AST와 함께 간질환의 진단에 널리 사용되는 효소로서 혈청 중 간독성으로 인해 간세포의 괴사와 간조직의 파괴가 진행됨에 따라 효소가 혈중으로 유리되어 혈장 내에서 활성이 증가함으로 이 효소의 활성은 간 손상의 지표로 이용된다. ALT (alanine aminotransferase) is a characteristic enzyme in cardiac muscle and hepatocyte, which increases the activity of serum in the tissue due to damage of the tissue, especially in chronic hepatitis. AST is an enzyme widely used for the diagnosis of liver disease. As the hepatocyte necrosis and hepatic tissue destruction are progressed due to the hepatic toxicity in the serum, the enzyme is released into the blood and the activity in the plasma is increased. .
표 11 및 도 20A에 나타난 바와 같이, ALT는 Normal control군에 비하여 은행나무의 형성층 유래 줄기세포(CMCs)군에서 유의적으로 감소함을 확인할 수 있었고 Vitamin C군보다도 감소경향을 나타내었다. 이는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 간을 보호하는 가능성이 있음을 시사한다. As shown in Table 11 and FIG. 20A, ALT was significantly decreased in the cambium-derived stem cell (CMCs) group than in the normal control group, and showed a tendency to be lower than that of the Vitamin C group. This suggests that stem cells from cambium stem cells (CMCs) may protect the liver.
한편, ALP (alkaline phosphatase)는 만성간염이나 간경변증에서도 올라갈 수 있으나, 만들어진 담즙이 간세포에서 잘 배출되지 못하거나 담도가 막혔을 때 현저히 증가한다. On the other hand, ALP (alkaline phosphatase) can be elevated in chronic hepatitis and cirrhosis, but it increases markedly when bile produced is not well released from hepatocytes or is blocked.
표 11 및 도 20B에 나타난 바와 같이, Normal control군, Vitamin C군, 은행나무의 형성층 유래 줄기세포(CMCs)군 모두 유사한 수치를 보여주었다.As shown in Table 11 and FIG. 20B, normal control group, Vitamin C group, and cambium-derived cambium-derived stem cells (CMCs) showed similar values.
AST (aspartate aminotransferase) 또한 심장근과 간세포 내에 있는 특성효소로서 조직세포의 손상에 의해 혈청중의 활성도가 증가되어지는데, 특히 만성간염의 경우 현저하게 증가된다. ALT와 함께 간질환의 진단에 널리 사용되는 효소로서 혈청 중 간독성으로 인해 간세포의 괴사와 간조직의 파괴가 진행됨에 따라 효소가 혈중으로 유리되어 혈장 내에서 활성이 증가함으로 이 효소의 활성은 간 손상의 지표로 이용된다. AST (aspartate aminotransferase) is also a characteristic enzyme in the cardiac muscle and hepatocyte, which increases the activity in the serum by the damage of the tissue cell, especially in chronic hepatitis. As an enzyme widely used for the diagnosis of liver disease with ALT, the enzyme is released into the blood as the necrosis of the hepatocyte and the destruction of the liver tissue are progressed due to the hepatotoxicity in the serum, and the activity of the enzyme is increased in the plasma, .
표 11 및 도 20C에 나타난 바와 같이, Normal control군에 비하여 Vitamin C군, 은행나무의 형성층 유래 줄기세포(CMCs)군에서 감소함을 확인할 수 있었다. 하지만, 통계적인 유의성은 나타나지 않았다.As shown in Table 11 and FIG. 20C, it was confirmed that the number of stem cells derived from cambium-derived stem cells (CMCs) of Vitamin C group and Ginkgo biloba decreased compared with that of the normal control group. However, there was no statistical significance.
LDH (lactate dehydrogenase)는 악성 종양세포에서 다량 생성되므로 암의 존재를 파악하는데 이용되어진다. LDH (lactate dehydrogenase) is produced in large numbers in malignant tumor cells and is used to detect the presence of cancer.
표 11 및 도 20D에 나타난 바와 같이, Normal control군에 비하여 Vitamin C군, 은행나무의 형성층 유래 줄기세포(CMCs)군에서 감소함을 확인할 수 있었다. 하지만, 통계적인 유의성은 나타나지 않았다.
As shown in Table 11 and FIG. 20D, it was confirmed that it decreased in the cambium-derived cambium-derived stem cells (CMCs) group compared to the normal control group. However, there was no statistical significance.
상기와 같은 Mouse 실험을 통하여 간 조직의 항산화 효소의 활성, 즉 GSH concentration, SOD activity, Catalase activity, GPx activity 측정과 혈청으로부터 간 기능의 혈액학적 간 지표물질인 ALT, AST, ALP, LDH를 측정한 결과는 은행나무의 형성층 유래 줄기세포(CMCs) 추출물이 생체 내에서 우수한 항산화 효과를 보유함을 제시한다.
In the mouse experiment, the activities of antioxidant enzymes such as GSH concentration, SOD activity, catalase activity, and GPx activity were measured and ALT, AST, ALP and LDH, which are hematological indexes of liver function, were measured The results suggest that cambium stem cells (CMCs) derived from cambium have excellent antioxidative effects in vivo.
은행나무의 형성층 유래 줄기세포(Stem cells derived from cambium CMCsCMCs ) 추출물의 ) Of the extract inin vivovivo 항염 효과 Anti-inflammatory effect
5% dextran sodium sulfate (DSS)를 음용수에 섞어 mouse에 5~7일간 투여하면 부종, 발적 및 궤양, 혈변을 동반한 급성 대장염이 대장 전반에 걸쳐 유발된다. 초기병변은 혈변, 체중감소, 대장의 축소 등이 나타나며 시간이 지나면서 형질세포 및 림프구가 침윤하게 되고 만성염증의 소견을 띄게 된다. DSS로 대장염을 유발시킨 동물 모델이 사람의 궤양성 대장염 증상과 유사한 증상을 나타내 가장 좋은 모델임이 보고된바 있다 (Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulfate colitis: cytokine profile and does dependency. Digestion 62: 240-248, 2000.). DSS induced colitis는 neutrophils and macrophage에 의해 주로 유도 되는 염증성 질환으로, 점막에서 염증을 유도하는 pro-inflammatory cytokine (IL-6, TNF-α)들에 의해 특징지어질 수 있다. 또한 최근 여러 연구들에서 DSS에서 유도되는 colitis는 T cell에서 분비되는 Th1 cytokine에 의해 질병이 심화 되는 것으로 알려져 있기 때문에, CD4+ effector T cell 에서 분비되는 Th1 type/Th2 type cytokines의 balance에 대한 연구는 염증성 질환 치료 및 예방에 중요 요소로 작용할 것으로 기대 된다. 본 실험에서는 CMCs 처리시 Th1 type cytokine, IFN-와 Th2 type cytokine, IL-4의 발현 양의 변화 및 pro-inflammatory cytokine (IL-6와 TNF-α)의 발현 양을 관찰함으로써 은행나무의 형성층 유래 줄기세포(CMCs)의 항염 효과를 입증하고자 하였다. 궤양성 대장염의 치료제로 주로 사용되는 sulfasalazine을 사용하여 은행나무의 형성층 유래 줄기세포(CMCs)와 비교 실험하였다.
When 5% dextran sodium sulfate (DSS) is mixed with drinking water for 5 to 7 days in mice, acute colitis accompanied by swelling, erythema, ulceration, and staphylococci is induced throughout the large intestine. Early lesions include stools, weight loss, and narrowing of the colon. Over time, plasma cells and lymphocytes infiltrate and develop chronic inflammation. An animal model of DSS-induced colitis has been reported to be the best model for human ulcerative colitis symptoms (Egger B, Bajaj-Elliott M, MacDonald T T, Inglin R, Eysselein VE, Buchler MW Characterization of acute murine dextran sodium sulfate colitis: cytokine profile and does dependency. Digestion 62: 240-248, 2000.). DSS-induced colitis is an inflammatory disease mainly induced by neutrophils and macrophages, and may be characterized by pro-inflammatory cytokines (IL-6, TNF-α) that induce inflammation in the mucosa. In addition, recent studies have shown that DSS-induced colitis is known to be exacerbated by Th1 cytokines secreted from T cells. Therefore, studies on the balance of Th1 type / Th2 type cytokines secreted from CD4 + effector T cells It is expected to play an important role in the treatment and prevention of inflammatory diseases. In this study, we examined the expression levels of Th1 type cytokines, IFN- and Th2 type cytokines, IL-4 and pro-inflammatory cytokines (IL-6 and TNF-α) And to demonstrate the anti-inflammatory effect of stem cells (CMCs). Sulfasalazine, which is mainly used for the treatment of ulcerative colitis, was used to compare cambium stem cells from cambium stem cells (CMCs).
9-1: 실험동물 사육 및 9-1: Experimental animal breeding and 실험군Experimental group
은행나무의 형성층 유래 줄기세포(CMCs)의 in vivo 항산화 효과를 위한 실험동물은 4주령의 암컷 Balb/c mouse 30마리를 오리엔트사(대전, 대한민국)로부터 구입하였다. 실험동물은 일정한 조건(온도: 22±2℃, 습도: 50~60%, 명암: 12시간 주기(07:00~19:00))하의 사육실에서 일반 고형사료와 물을 무제한 공급하면서 1주 동안 적응시킨 후 실험에 사용하였다. Balb/c mouse를 6마리씩 5군(Normal control군, DSS군, DSS+SS군, DSS+CMCs군, CMCs+DSS+CMCs)으로 나누어 실험하였다. 증류수에 Dextran sulfate sodium(5%, W/V)을 첨가하여 5일간 식수대용으로 자유 공급시켜 급성 대장염을 유발시켰다. 그 후 DSS군(대조군)은 치료제를 공급하지 않았고, DSS+SS군(양성 대조군)은 급성 대장염을 유발시킨 후 치료제로 사용되는 sulfasalazine 사료(1 mg/day/마리)를 2주간 자유 섭취시켰다. 그리고 DSS+CMCs군은 급성 대장염을 유발시킨 후 은행나무의 형성층 유래 줄기세포(CMCs) 사료를 2주간 자유 섭취시켰으며, CMCs+DSS+CMCs군은 DSS로 급성 대장염을 유발시키기 전에 먼저 은행나무의 형성층 유래 줄기세포(CMCs) 사료 (100 mg/day/마리)를 1주간 먹인 후 급성 대장염을 유발시키는 동안에도 계속 은행나무의 형성층 유래 줄기세포(CMCs) 사료를 2주간 자유 섭취시켰다. 이때, 은행나무의 형성층 유래 줄기세포(CMCs)는 동결건조된 은행나무의 형성층 유래 줄기세포(CMCs)를 사료와 혼합하여 제형화하여 자유급식하였다.
Bank of cambium-derived stem cells (CMCs) of wood in For the vivo antioxidant effect, 30 female Balb / c mice of 4 weeks old were purchased from Orient (Daejeon, Korea). Experimental animals were maintained in feeder room under constant conditions (temperature: 22 ± 2 ℃, humidity: 50-60%, darkness: 12 hour period (07: 00 ~ 19: 00) After adaptation, it was used in the experiment. Six Balb / c mice were divided into 5 groups (normal control group, DSS group, DSS + SS group, DSS + CMCs group, CMCs + DSS + CMCs). Dextran sulfate sodium (5%, W / V) was added to the distilled water to induce acute colitis by free feeding for drinking water for 5 days. Thereafter, the DSS group (control group) did not receive any treatment, and the DSS + SS group (positive control group) was free to ingest sulfasalazine feed (1 mg / day / horse) for 2 weeks after inducing acute colitis. In addition, the DSS + CMCs group had free radical ingestion of cambium stem cells (CMCs) for 2 weeks after inducing acute colitis, and CMCs + DSS + CMCs group was treated with DSS before inducing acute colitis. (CMCs) feedstuffs (100 mg / day / horses) were fed for 1 week, and then the CMCs feeds of CMCs were gavaged for 2 weeks while acute colitis was induced. At this time, cambium - derived stem cells (CMCs) were prepared by mixing cambium - derived stem cells (CMCs) from lyophilized Ginkgo biloba with feed, and fed free.
9-2: 혈액 채취9-2: Blood collection
실험 종료 시 각 군의 혈액을 안와정맥에서 채취하여 30분간 실온에서 방치, 혈액을 응고시켜 4℃에서 3,000 rpm으로 15분간 원심분리 한 후 얻은 상등액(혈청)을 수거하여 -80℃ 초저온 냉동고에 보관하였다.
At the end of the experiment, the blood of each group was collected from the orbital vein, left at room temperature for 30 minutes, and the blood was frozen and centrifuged at 3,000 rpm for 15 minutes at 4 ° C. The resulting supernatant (serum) was collected and stored in a -80 ° C cryocooler Respectively.
9-3: 은행나무의 형성층 유래 줄기세포(9-3: Stem cells from the cambium of cambium CMCsCMCs )가 )end mousemouse 의 대장 길이와 상태 및 체중에 미치는 영향On the length, condition and body weight of colon
혈액을 채취한 mouse는 경추탈구 시킨 후 대장을 절단하여 대장 길이를 측정하고 상태를 육안으로 확인하였다. The mice were sacrificed after cervical dislocation and the colon was cut and the length of the colon was measured and visualized by visual observation.
실험동물의 대장 길이와 그 상태를 조사한 결과, 도 21A에 나타난 바와 같이, Normal control군(56 mm)을 기준으로 대장의 길이를 살펴보면 DSS군(51 mm)은 짧아졌고 DSS+SS군과 DSS+CMCs군(56 mm)은 비슷하나 CMCs+DSS+CMCs군(64 mm)은 오히려 길어졌음을 알 수 있었다. DSS군의 대장 두께는 다른 군들에 비하여 일정하지 않고 백색에 가까운 색상을 띄고 있었으며 분변 강도 또한 가장 묽어 보였고 중앙으로만 쏠려있음을 관찰 할 수 있었다. DSS+SS군과 DSS+CMCs군의 대장 상태는 Normal control군과 유사한 경향을 보였는데 중간정도의 붉은 색상을 띄고 있으며 분변의 강도는 Normal control군 보다는 묽어 보였다. CMCs+DSS+CMCs군의 대장 상태는 밝은 선홍색을 띄고 있으며 분변의 강도는 오히려 Normal control군 보다 좋아 보였다.As shown in FIG. 21A, the length of the colon was shorter in the normal control group (56 mm) than in the DSS + SS group and the DSS + CMCs (56 mm) were similar but CMCs + DSS + CMCs (64 mm) were longer. The thickening of the colon in the DSS group was not constant compared to other groups, and the color was close to white. The fecal intensity was also the thinnest, and it was observed to be concentrated only in the center. The colonic status of the DSS + SS group and the DSS + CMCs group showed a similar tendency to that of the normal control group, with a moderate red color, and the intensity of the feces was thinner than that of the normal control group. The colonic status of the CMCs + DSS + CMCs group was brightly reddish, and the intensity of the feces was better than that of the normal control group.
또한 각 실험군의 평균 체중을 측정한 결과, 도 21B에 나타난 바와 같이, 각 실험군의 평균 체중은 급성 대장염을 유발시킨 후 CMCs+DSS+CMCs군(5일째), DSS+CMCs군(6일째), DSS+SS와 DSS 단독처리군(7일째) 점차 증가하였고, 체중의 회복정도 또한 CMCs+DSS+CMCs 군이 가장 양호하게 회복되는 것을 알 수 있었다.
As shown in FIG. 21B, the mean body weight of each experimental group was determined by CMCs + DSS + CMCs (5 days), DSS + CMCs (6 days) DSS + SS and DSS alone group (7th day) gradually increased, and the recovery of body weight was also recovered the best in CMCs + DSS + CMCs group.
9-4: 은행나무의 형성층 유래 줄기세포(9-4: Stem cells derived from the cambium of cambium CMCsCMCs )가 대장 내 ) In the colon 분변의Fecal IgAIgA 농도에 미치는 영향 Effect on concentration
소화관은 영양원이 되는 음식물을 소화 흡수할 뿐만 아니라 virus, 병원미생물 등 생체에 유해한 이물질을 배제하는 중요한 면역장기이다. 소화관에는 장관 상피의 임파구(lymphocyte), 점막 고유층(lamina propria)의 임파구, Payer's patch 등으로부터 구성되는 장관 관련 임파구 조직이 존재하여 효과적인 생체방어기구를 형성하고 있다. 면역 글로불린(immunoglobulin, Ig)은 항체로서의 기능을 담당하는 일군의 단백질이며 생체의 체액성 면역에 중요한 역할을 담당한다. 특히, 소화관 점막 상피세포에서 분비되는 분비형 IgA 항체는 소장에서 대량으로 생산되어 유해물질의 흡수억제, 항원에 대한 중화 및 제거 등을 통하여 점막면역기구의 중심역할을 한다. The digestive tract is an important immune organ that not only digests and absorbs food that is a nutrient source but also eliminates harmful foreign substances such as viruses and hospital microorganisms. The gastrointestinal tract is composed of a lymphocyte of the epithelium of the intestine, lymphocytes of the lamina propria, and Payer's patch, thus forming an effective biologic defense mechanism. Immunoglobulins (Ig) are a group of proteins that function as antibodies and play an important role in the humoral immune response of the body. In particular, secretory IgA antibodies secreted from the gut mucosa epithelial cells are produced in large quantities in the small intestine and play a central role in the mucosal immune system through inhibition of absorption of harmful substances, neutralization and elimination of antigens.
따라서, 대장 내 분변에 들어있는 IgA의 농도를 측정하기 위하여 대장을 protease inhibitor가 들어있는 PBS 용액에 넣어 잘게 조각낸 다음 vortex로 균질화 하였다. 이 용액을 원심분리(4℃, 12,000 rpm, 10분)한 후, 상층액을 채취하여 IgA항체를 이용하여 대장 내 분변의 IgA 농도를 측정하였다. Therefore, in order to measure the concentration of IgA in the intestinal feces, the colon was put into PBS solution containing protease inhibitor and finely divided and homogenized with a vortex. After centrifugation (4 ° C, 12,000 rpm, 10 minutes), the supernatant was collected and the IgA concentration in the intestinal feces was measured using IgA antibody.
먼저 ELISA plate 표면에 분변 상층액을 coating buffer (0.1 M carbonate, pH 9.5)로 고정시키기 위하여 4℃에서 하룻밤 반응시켰다. Plate를 0.05% Tween-20이 포함된 1x PBS (PBS-T)로 5회 세척한 다음 2% BSA가 포함된 1x assay diluent 용액으로 실온에서 2시간 blocking하였다. Plate를 1x PBS-T로 3회 세척한 다음, alkaline phosphate (AP)가 결합된 anti-mouse Ig A를 넣어 실온에서 2시간 반응시켰다. Plate를 다시 1x PBS-T로 5회 세척한 다음 AP기질용액인 Phosphatase substrate를 넣고 Plate의 반응 정도를 microplate reader에서 405 nm 흡광도로 측정하였다. 이때 표준물질로는 mouse IgA를 사용하였다.First, the supernatant was allowed to react overnight at 4 ° C in a coating buffer (0.1 M carbonate, pH 9.5) on the surface of the ELISA plate. Plate was washed 5 times with 1x PBS (PBS-T) containing 0.05% Tween-20 and then blocked with 1x assay diluent solution containing 2% BSA for 2 hours at room temperature. The plate was washed three times with 1x PBS-T, and then reacted with alkaline phosphate (AP) conjugated anti-mouse Ig A for 2 hours at room temperature. Plate was washed 5 times with 1x PBS-T, and then the AP substrate solution, Phosphatase substrate, was added. The reaction rate of the plate was measured with a microplate reader at 405 nm absorbance. Mouse IgA was used as a reference material.
ELISA를 이용하여 대장 내에 있는 IgA 농도를 측정한 결과, 표 12 및 도 22에 나타난 바와 같이, DSS 단독 처리군에서만 높게 나타났다. 이 결과는 점막의 epithelial cell에 있는 polymeric immunoglobulin receptor (pIgR)에 의해 lumen으로 분비되는 IgA의 경우 normal mouse 에 비해 DSS에 의한 colitis가 유도 되었을 때 5배 이상 대장 내로 증가 된 것으로 미루어 염증질환에 의한 조직 손상을 예측 할 수 있었다. 이에 반해 DSS+SS군, DSS+CMCs군 그리고 CMCs+DSS+CMCs군의 IgA 분비량은 변화가 거의 없게 측정되었기 때문에, SS나 은행나무의 형성층 유래 줄기세포(CMCs)에 의한 염증 완화로 인해 점막 조직의 손상이 적게 일어났음을 알 수 있었다.
As a result of measuring the IgA concentration in the large intestine using an ELISA, as shown in Table 12 and FIG. 22, it was higher only in the DSS alone treatment group. This result suggests that IgA secreted by lumen by polymeric immunoglobulin receptor (pIgR) in mucosal epithelial cells is increased in the colon more than 5 times when colitis caused by DSS is induced compared to normal mouse. Damage could be predicted. In contrast, IgA secretion levels in the DSS + SS, DSS + CMCs, and CMCs + DSS + CMCs groups were almost unchanged, suggesting that mucosal tissues And that the damage was less.
9-5: 은행나무의 형성층 유래 줄기세포(9-5: Stem cells from cambium-derived cambium CMCsCMCs )가 )end MesentericMesenteric lymphlymph nodenode (( MLNMLN ) 임파구 배양액의 ) Of the lymphocyte culture cytokinecytokine 농도에 미치는 영향 Effect on concentration
각 마우스 장관 임파절(MLN)을 적출한 후 collagenase solution으로 dissociation 시켜 mono cell 상태의 cell을 percoll gradient를 이용하여 lymphocyte를 분리한 다음, 10% FBS가 함유된 RPMI 1640 medium에 부유시켜 24 well plate에 2x106 cells/well의 농도로 분주하고 lymphocyte의 증식을 촉진시키기 위하여 2 ㎍/mL의 농도로 Con A를 첨가한 후 5% CO2 incubator에서 24 hr(IFN-γ, TNF-α) 또는 48 hr (IL-4, IL-6) 배양하였다. Each mouse intestinal lymph node (MLN) was extracted and dissociated with collagenase solution. Monoclonal cells were separated by percoll gradient and then suspended in RPMI 1640 medium containing 10% FBS. 6 cells / divider as well concentration of and after the addition of Con a with 2 ㎍ / mL concentration in order to promote the proliferation of lymphocyte in 5% CO 2 incubator 24 hr ( IFN-γ, TNF-α) or 48 hr ( IL-4, and IL-6).
점막층은 섭취한 장 내용물들이 장관 내부에서 잘 흘러가도록 장관 내 표면에 윤활유 같은 작용을 하며, 하부에 존재하는 장관 세포에 화학적, 미생물학적, 물리적 손상이 가해질 때에 방어력을 지니는 제1차 방어선 역할을 담당하는데, 이 장관 상피세포에 강한 세균들이 침입하게 되면 염증 촉진 사이토카인과 그에 의한 mRNA들이 매우 급속도로 방출되므로, 이에 DSS 섭취에 의한 염증성 사이토카인(IL-4, IL-6: 48 hr 배양, IFN-, TNF-a: 24 hr 배양)에 은행나무의 형성층 유래 줄기세포(CMCs)가 어떤 영향을 미치는지 ELISA 방법으로 측정하였다.The mucosal layer acts like a lubricant on the surface of the intestinal tract so that the intestinal contents can flow well inside the intestinal tract and acts as a primary line of defense when chemical, microbiological and physical damage is applied to the intestinal cells present in the lower intestine. (IL-4, IL-6, 48 hr, IFN) by DSS ingestion, because inflammatory cytokines and their mRNAs are rapidly released when intestinal microorganisms invade intestinal epithelial cells. -, TNF-a: 24 hr cultures) were examined by ELISA method to determine the effect of cambium stem cells (CMCs) derived from cambium.
먼저 각 사이토카인의 capture antibody를 96-well ELISA plate에 넣고 4℃에서 하룻밤 반응시켰다. Plate를 0.05% Tween-20이 포함된 1x PBS (PBS-T)로 5회 세척한 다음 2% BSA가 포함된 1x assay diluent 용액으로 실온에서 2시간 blocking하였다. Plate를 1x PBS-T로 3회 세척한 다음, 세포 배양액 또는 각 사이토카인 표준단백질을 넣어 2시간 동안 실온에서 반응시켰다. 이를 다시 1x PBS-T로 5회 세척하고 detection antibody를 넣어 실온에서 2시간 반응시켰다. Plate를 다시 1x PBS-T로 5회 세척하고 avidin-HRP 용액을 넣어 실온에서 30분간 반응시켰다. 이를 1x PBS-T용액으로 7회 세척한 다음 TMB 기질용액을 넣고 최종 15분간 실온에서 반응시키고, 반응정지액(H3PO4)을 첨가하여 반응을 정지시켰다. Plate의 반응 정도를 microplate reader에서 430 nm 흡광도로 측정하였다. 이때 표준물질로 각각의 recombinant를 사용하였다. First, each cytokine capture antibody was added to a 96-well ELISA plate and reacted overnight at 4 ° C. Plate was washed 5 times with 1x PBS (PBS-T) containing 0.05% Tween-20 and then blocked with 1x assay diluent solution containing 2% BSA for 2 hours at room temperature. The plate was washed three times with 1x PBS-T, and the cell culture medium or each cytokine standard protein was added thereto, followed by reaction at room temperature for 2 hours. The cells were washed 5 times with 1x PBS-T and incubated for 2 hours at room temperature. The plate was washed 5 times with 1x PBS-T, and the avidin-HRP solution was added and reacted at room temperature for 30 minutes. The reaction mixture was washed with 1x PBS-
ELISA를 이용하여 점막의 면역 시스템에서 중요한 역할을 하는, MLN 임파구 배양액에서 cytokine을 측정한 결과, 표 13 및 도 23에 나타난 바와 같이, DSS에 의해 colitis가 유도됨이 IFN-γ, TNF-α와 IL-6의 발현이 증가됨을 통해 확인할 수 있었다. 질병 완화의 control로 사용된 DSS+SS군의 경우 Th2 type cytokine, IL-4의 발현이 증가 되고 상대적으로 IFN-γ, TNF-a, 와 IL-6이 감소하였기 때문에 Th2 type cytokine과 Th1 type cytokine의 발현 balance 작용에 의한 결과로 해석되며, 이러한 현상은 은행나무의 형성층 유래 줄기세포(CMCs)를 먹인 그룹이 보다 높은 효율로 유도된 것을 알 수 있어 은행나무의 형성층 유래 줄기세포(CMCs)의 염증 완화 치료제의 가능성을 확인할 수 있었다.
As shown in Table 13 and FIG. 23, cytokine was measured in the MLN lymphocyte culture medium, which plays an important role in the mucosal immunity system using ELISA. As shown in Table 13 and FIG. 23, IFN-γ, TNF- IL-6 expression was increased. In the DSS + SS group used for the control of disease, Th2 type cytokine, Th1 type cytokine and Th1 type cytokine were detected because IL-4 expression was increased and IFN-γ, TNF-a and IL- (CMCs) from the gingko stem were more efficiently induced than those from the gingko stem-derived stem cells (CMCs) of Ginkgo biloba. The possibility of a palliative treatment was confirmed.
mean±st.erIL-4
mean ± st.er
mean±st.erIL-6
mean ± st.er
mean±st.erIFN-y
mean ± st.er
mean±st.erTNF-a
mean ± st.er
9-6: 은행나무의 형성층 유래 줄기세포(9-6: Stem cells from cambium-derived cambium CMCsCMCs )가 혈청 ) Was serum IgAIgA , , IgGIgG 농도에 미치는 영향 Effect on concentration
동물은 세균, 바이러스, 그 외의 비자기 단백질(foreign protein)등 여러 종류의 항원에 대하여 항체를 만들고 이들 항원에 대해 방어를 하게 된다. 각각의 항원에 대하여 만들어진 항체들은 주어진 항원과 반응하여 그들을 무기력화 시킨다. 항체는 immunoglobulin이라고도 불리며 포유동물의 혈액이나 침, 모유 등에서 발견된다. 분비액내의 IgA는 미생물 침입에 대한 첫번째 방어선으로 작용하며 위장 감염을 막는데 중요한 역할을 한다. Animals produce antibodies against a variety of antigens, including bacteria, viruses, and other foreign proteins, and defend against these antigens. Antibodies made against each antigen react with a given antigen and render them helpless. Antibodies , also called immunoglobulins, are found in the blood, saliva, and breast milk of mammals. IgA in the secretion fluid acts as the first line of defense against microbial invasion and plays an important role in preventing gastrointestinal infection.
IgA는 호흡기 점막, 장점막 및 분비선에 존재하는 plasma cell에서 일차적으로 합성된 후 일부 IgA는 혈액으로 들어가며 대부분은 상피 세포내 또는 그 사이에 존재한다. 상피세포사이에 존재하는 IgA를 분비형 IgA (secretory IgA, sIgA)라 하는데 효소에 저항성을 갖는다. 또한 혈액 중 항체의 75%정도를 차지하는 것이 IgG인데 세균 항체, 바이러스 중화 항체, 침전 항체, 혈구 응집소와 용혈소의 대부분이 IgG이다. IgA is synthesized primarily in plasma cells present in respiratory mucosa, intestinal mucosa, and glands, and some IgA enters the blood and most of it is present in or between epithelial cells. IgA between the epithelial cells is called secretory IgA (secretory IgA, sIgA) and is resistant to enzymes. In addition, IgG accounts for 75% of the antibodies in blood. IgG is the majority of bacterial antibodies, virus neutralizing antibodies, precipitating antibodies, hemagglutinins and hemolysins.
따라서, 은행나무의 형성층 유래 줄기세포(CMCs)가 DSS에 의해 유도된 colitis mouse 혈청 IgA와 IgG에 어떤 영향을 미치는지 ELISA 방법을 이용하여 측정하였다.
Therefore, we investigated the effect of cambium stem cells (CMCs) on the serum IgA and IgG of colitis mouse induced by DSS using ELISA method.
mean±std.errIgA
mean ± std.err
mean±std.errIgG
mean ± std.err
그 결과, 표 14 및 도 24A에 나타난 바와 같이, 혈중 IgA 농도는 DSS 단독 처리군이 가장 높게 나타났고 DSS+SS, DSS+은행나무CMCs, CMCs+DSS+CMCs군이 Normal control군 보다는 높게 나타났으며, 표 14 및 도 24B에 나타난 바와 같이, 혈중 IgG 농도는 DSS only군이 가장 낮게 나타났고 DSS+SS, DSS+CMCs, CMCs+DSS+CMCs군이 Normal control군과 비슷하게 나타났다. As a result, as shown in Table 14 and FIG. 24A, serum IgA concentration was highest in DSS alone group, DSS + SS, DSS + Ginkgo CMCs, CMCs + DSS + CMCs group were higher than normal control group As shown in Table 14 and FIG. 24B, serum IgG concentration was lowest in DSS only group and DSS + SS, DSS + CMCs, CMCs + DSS + CMCs group were similar to normal control group.
이전에 알려진 보고들처럼 DSS에 의해 유도된 colitis mouse 에서는 normal에 비해 IgG 발현이 적고 IgA 발현이 증가 된 것을 확인하였다. 이때, positive control인 SS나 은행나무의 형성층 유래 줄기세포(CMCs)를 먹인 군에서 IgA와 IgG의 정상수치로의 변화를 보아 염증완화에 의한 결과로 판단된다.
As previously reported, colitis mice induced by DSS showed less IgG expression and increased IgA expression compared to normal. At this time, it is considered that the result of inflammation relieved the change of IgA and IgG to the normal value in the fed group of positive control SSCs and cambium stem cells derived from cambium (CMCs).
9-7: 은행나무의 형성층 유래 줄기세포(9-7: Stem cells from cambium-derived cambium CMCsCMCs )가 비장 ) Is spleen 임파구Lymphocyte 배양액의 cytokine 농도에 미치는 영향 Effect on the cytokine concentration of culture medium
각 군의 mouse spleen을 적출한 후 splenocyte를 분리하여 10% FBS가 함유된 RPMI 1640 medium에 부유시켜 24 well plate에 2x106 cells/well의 농도로 분주하고 splenocyte의 증식을 촉진시키기 위하여 2 ㎍/mL의 농도로 Con A를 첨가한 후 5% CO2 incubator에서 24 hr 또는 48 hr 배양하였다. Splenocytes were isolated from each group and suspended in RPMI 1640 medium containing 10% FBS. The cells were seeded at a concentration of 2 × 10 6 cells / well in a 24-well plate. To promote splenocyte proliferation, 2 μg / mL Con A was added at a concentration of 5% CO 2 incubator for 24 hr or 48 hr.
점막층은 섭취한 장 내용물들이 장관 내부에서 잘 흘러가도록 장관 내 표면에 윤활유 같은 작용을 하며, 하부에 존재하는 장관 세포에 화학적, 미생물학적, 물리적 손상이 가해질 때에 방어력을 지니는 제1차 방어선 역할을 담당하며, 이 장관 상피세포에 강한 세균들이 침입하게 되면 염증 촉진 사이토카인과 그에 의한 mRNA들이 매우 급속도로 방출되므로, 이에 DSS 섭취에 의한 염증 사이토카인(IL-4, IL-6: 48 hr 배양, IFN-, TNF-a: 24 hr 배양)에 은행나무의 형성층 유래 줄기세포(CMCs)가 어떤 영향을 미치는지 ELISA 방법으로 측정하였다. The mucosal layer acts like a lubricant on the surface of the intestinal tract so that the intestinal contents can flow well inside the intestinal tract and acts as a primary line of defense when chemical, microbiological and physical damage is applied to the intestinal cells present in the lower intestine. (IL-4, IL-6: 48 hr, IFN-induced) by DSS ingestion, because inflammatory cytokines and their mRNAs are rapidly released when intestinal microorganisms invade intestinal epithelial cells. -, TNF-a: 24 hr cultured) were examined by ELISA method to determine the effect of cambium stem cells (CMCs) derived from cambium.
mean±st.erIL-4
mean ± st.er
mean±st.erIL-6
mean ± st.er
mean±st.erIFN-y
mean ± st.er
mean±st.erTNF-a
mean ± st.er
전신 면역 기관에서의 DSS-induced colites에 의한 Th1 type T cell들의 영향을 확인하고자 spleen 임파구 배양액으로부터 각 cytokine을 확인한 결과, 표 15 및 도 25에 나타난 바와 같이, DSS에 의해 유도된 colitis mouse에서 normal mouse에 비해 상대적으로 Th1 type cytokine 및 pro-inflammatory cytokine의 증가를 확인 하였으며, 이는 MLN의 결과와 마찬가지로 SS나 은행나무의 형성층 유래 줄기세포(CMCs)를 먹인 군이 Th2 type cytokine 증가에 따른 Th1 type cytokine 및 pro-inflammatory cytokine의 발현양의 감소로 인해 염증 반응이 완화된 것으로 기대된다.In order to examine the effect of Th1 type T cells on DSS-induced colites in the whole body immunity, each cytokine was examined from the spleen lymphocyte culture medium. As shown in Table 15 and FIG. 25, (CMCs) in the SS or Ginkgo biloba showed a significant increase in Th1-type cytokine and pro-inflammatory cytokine compared with the Th1-type cytokine The inflammatory response is expected to be mitigated by the decrease in the expression level of pro-inflammatory cytokine.
DSS에 의해 유도된 colitis mouse의 은행나무의 형성층 유래 줄기세포(CMCs)를 이용한 in vivo 항염 효과(대장 조직의 육안 관찰, 대장내 분변의 IgA 농도, MLN 임파구 배양액의 cytokine 측정, 혈청에서의 IgA, IgG농도 측정, 비장 임파구 배양액의 cytokine 측정 등)를 실험한 결과 우수한 항염 효과를 보유함을 알 수 있었다.
In using the cambium-derived stem cells (CMCs) of the ginkgo tree colitis mouse induced by DSS vivo The anti-inflammatory effect (visual observation of colon tissue, IgA concentration in intestine, cytokine measurement in MLN lymphocyte culture, measurement of IgA and IgG concentration in serum, cytokine measurement in spleen lymphocyte culture, etc.) And it was found.
제조예Manufacturing example 1. One. 약학제제Pharmaceutical preparation 제조예Manufacturing example
제제예Formulation example 1-1: 정제의 제조 1-1: Preparation of tablets
실시예 2에서 제조된 줄기세포 추출물 100 ㎎을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎을 혼합하여 통상의 정제제조방법에 따라 제조하였다.100 mg of the stem cell extract prepared in Example 2 was prepared by mixing 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate according to a conventional purification method.
제제예Formulation example 1-2: 캡슐제의 제조 1-2: Preparation of capsules
실시예 2에서 제조된 줄기세포 추출물 500 ㎎을 연질 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.500 mg of the stem cell extract prepared in Example 2 was filled in soft gelatin capsules to prepare capsules.
제제예Formulation example 1-3: 시럽제의 제조 1-3: Preparation of Syrup
실시예 1에서 수득한 줄기세포 1 g, 이성화당 10 g, 만니톨 5 g, 적량의 정제수의 함량으로 통상적인 액제제의 제조방법에 따라 100 mL의 시럽제를 제조하였다.100 mL of a syrup was prepared according to a conventional method for preparing a liquid preparation, based on 1 g of the stem cells obtained in Example 1, 10 g of isomerized sugar, 5 g of mannitol, and an appropriate amount of purified water.
제제예Formulation example 1-4: 주사제의 제조 1-4: Preparation of injection
실시예 2에서 제조된 줄기세포 추출물 200 ㎎을 폴리옥시에틸렌 수소화 카스트로 오일을 함유하는 생리 식염수 200 ㎎에 가열 용해시켜 혼합 추출물을 0.1%의 농도로 함유하는 주사제를 제조하였다.
200 mg of the stem cell extract prepared in Example 2 was dissolved in 200 mg of physiological saline containing polyoxyethylene hydrogenated castor oil under heating to prepare an injection containing the mixed extract at a concentration of 0.1%.
제조예Manufacturing example 2. 기능성 식품의 제조 2. Manufacture of functional food
제조예Manufacturing example 2-1: 기능성 음료의 제조 2-1: Preparation of functional beverage
실시예 1에서 수득한 줄기세포 200㎎을 96㎖의 물에 용해시킨 후 보조제로서 비타민 C 500㎎, 교미제로서 구연산, 올리고당을 각각 1g 가하고, 보존재로서 나트륨벤조에이트 0.05g을 가한 후 정제수를 가하여 전량을 100㎖로 만들어 기능성 음료를 제조하였다.200 mg of the stem cells obtained in Example 1 were dissolved in 96 ml of water, 500 mg of vitamin C as an adjuvant, 1 g of citric acid and oligosaccharide as a mating agent were added, 0.05 g of sodium benzoate was added thereto, and purified water To make a total volume of 100 ml to prepare a functional beverage.
제조예Manufacturing example 2-2: 기능성 음료의 제조 2-2: Production of functional beverage
실시예 2에서 제조한 줄기세포 추출물 200 ㎎을 96 mL 물에 용해시킨 후 보조제로서 비타민 C 500㎎, 교미제로서 구연산, 올리고당을 각각 1 g 가하고, 보존재로서 나트륨벤조에이트 0.05 g을 가한 후 정제수를 가하여 전량을 100 mL로 만들어 기능성 음료를 제조하였다.
After 200 mg of the stem cell extract prepared in Example 2 was dissolved in 96 mL of water, 500 mg of vitamin C as an adjuvant, 1 g of citric acid and oligosaccharide as a mating agent were added, and 0.05 g of sodium benzoate was added thereto as a beverage. To make 100 mL of the total amount.
이상으로 본 발명의 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
<110> UNHWA CORPORATION
<120> Anti-inflammatory composition comprising plant stem cell derived
from cambium of family ginkgoaceae
<130> P10-B315
<160> 6
<170> KopatentIn 1.71
<210> 1
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> COX-2 gene Forward primer
<400> 1
aagaagaaag ttcattcctg atccc 25
<210> 2
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> COX-2 gene Reverse primer
<400> 2
tgactgtggg aggatacatc tctcc 25
<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> iNOS gene Forward primer
<400> 3
ctgcagcact tggatcagga acctg 25
<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> iNOS gene Reverse primer
<400> 4
gggagtagcc tgtgtgcacc tggaa 25
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> GAPDH gene Forward primer
<400> 5
ccgatgcccc catgtttgtg 20
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> GAPDH gene Reverse primer
<400> 6
ggccatgcca gtgagcttcc 20
<110> UNHWA CORPORATION
<120> Anti-inflammatory composition comprising plant stem cell derived
from cambium of family ginkgoaceae
<130> P10-B315
<160> 6
<170> Kopatentin 1.71
<210> 1
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> COX-2 gene Forward primer
<400> 1
aagaagaaag ttcattcctg atccc 25
<210> 2
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> COX-2 gene Reverse primer
<400> 2
tgactgtggg aggatacatc tctcc 25
<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> iNOS gene Forward primer
<400> 3
ctgcagcact tggatcagga acctg 25
<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> iNOS gene Reverse primer
<400> 4
gggagtagcc tgtgtgcacc tggaa 25
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> GAPDH gene Forward primer
<400> 5
ccgatgcccc catgtttgtg 20
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> GAPDH gene Reverse primer
<400> 6
Claims (22)
An anti-inflammatory composition comprising at least one of cambium-derived stem cells derived from Ginkgo biloba cambium, an extract thereof, and a culture thereof, which is a native undifferentiated cell derived from a cambium (Ginkgo biloba) cambium.
(a) 현탁배양 시 은행나무의 탈분화된 캘러스에 비하여 많은 수의 단세포를 포함하거나 작은 사이즈의 세포 집합체를 포함함;
(b) 다수의 액포(vacuole)를 가지는 형태학적 특징을 나타냄;
(c) 은행나무의 탈분화된 캘러스에 비하여 활성이 증가된 미토콘드리아를 가짐;
(d) 은행나무의 탈분화된 캘러스에 비하여 생장속도가 빠르고 오랫동안 성장할 수 있음; 및
(e) 은행나무의 탈분화된 캘러스에 비하여 생물반응기에서 전단 스트레스(shear stress)에 대해 낮은 민감성을 가짐.
The anti-inflammatory composition according to claim 1, wherein the cambium stem cell derived from cambium has at least one of the following characteristics:
(a) contains a large number of single cells or a small-sized cell aggregate as compared to the dedifferentiated callus of ginkgo in suspension culture;
(b) exhibits morphological features with multiple vacuoles;
(c) has an increased activity of mitochondria compared to demineralized callus of ginkgo;
(d) Growth rate is faster and longer than ginkgo's demineralized callus; And
(e) Has low sensitivity to shear stress in bioreactors as compared to demineralized callus of ginkgo.
3. The anti-inflammatory composition according to claim 2, wherein the cambium-derived cambium stem cells have at least two of the characteristics (a) to (e).
The anti-inflammatory composition according to claim 2, wherein the cambium-derived cambium-derived stem cells have at least three of the characteristics (a) to (e).
[3] The anti-inflammatory composition according to claim 2, wherein the cambium-derived cambium-derived stem cells have at least four characteristics of (a) to (e).
The anti-inflammatory composition according to claim 2, wherein the cambium-derived cambium-derived stem cells have the characteristics (a) to (e).
(a) 은행나무로부터 형성층 함유 조직을 수득하는 단계;
(b) 상기 수득된 형성층 함유 조직을 배지에서 배양하는 단계; 및
(c) 상기 배양된 조직의 캘러스로부터 분리된 형성층으로부터 형성층 유래 줄기세포를 수득하는 단계.
The anti-inflammatory composition according to claim 1, wherein the cambium-derived cambium-derived stem cells are separated by a separation method comprising the steps of:
(a) obtaining a cambium-containing tissue from ginkgo;
(b) culturing the obtained cambium-containing tissue in a medium; And
(c) obtaining cambium-derived stem cells from cambium separated from calli of said cultured tissue.
2. The method of claim 1, wherein the culture comprises contacting the stem cells with 3-5% (g / L) raw sugar or sugar; And methyl jasmonate. ≪ RTI ID = 0.0 > 21. < / RTI >
The anti-inflammatory composition according to claim 1, wherein the extract is extracted using a solvent selected from the group consisting of distilled water, alcohol, acetone, dimethyl sulfoxide (DMSO), and a mixed solvent thereof.
A functional food for preventing or ameliorating inflammation, which contains at least one of cambium-derived stem cells derived from Ginkgo biloba cambium derived from Ginkgo biloba cambium, undifferentiated undifferentiated cells, extract thereof and cultures thereof.
(a) 현탁배양 시 은행나무의 탈분화된 캘러스에 비하여 많은 수의 단세포를 포함하거나 작은 사이즈의 세포 집합체를 포함함;
(b) 다수의 액포(vacuole)를 가지는 형태학적 특징을 나타냄;
(c) 은행나무의 탈분화된 캘러스에 비하여 활성이 증가된 미토콘드리아를 가짐;
(d) 은행나무의 탈분화된 캘러스에 비하여 생장속도가 빠르고 오랫동안 성장할 수 있음; 및
(e) 은행나무의 탈분화된 캘러스에 비하여 생물반응기에서 전단 스트레스(shear stress)에 대해 낮은 민감성을 가짐.
13. The functional food according to claim 12, wherein the cambium stem cell derived from cambium has at least one of the following characteristics:
(a) contains a large number of single cells or a small-sized cell aggregate as compared to the dedifferentiated callus of ginkgo in suspension culture;
(b) exhibits morphological features with multiple vacuoles;
(c) has an increased activity of mitochondria compared to demineralized callus of ginkgo;
(d) Growth rate is faster and longer than ginkgo's demineralized callus; And
(e) Has low sensitivity to shear stress in bioreactors as compared to demineralized callus of ginkgo.
14. The functional food according to claim 13, wherein the cambium-derived cambium stem cell has at least two of the characteristics (a) to (e).
14. The functional food according to claim 13, wherein the cambium-derived cambium-derived stem cells have at least three of the characteristics (a) to (e).
14. The functional food according to claim 13, wherein the cambium-derived cambium-derived stem cells have at least four characteristics of (a) to (e).
14. The functional food according to claim 13, wherein the cambium stem cell derived from cambium has the characteristics (a) to (e).
(a) 은행나무로부터 형성층 함유 조직을 수득하는 단계;
(b) 상기 수득된 형성층 함유 조직을 배지에서 배양하는 단계; 및
(c) 상기 배양된 조직의 캘러스로부터 분리된 형성층으로부터 형성층 유래 줄기세포를 수득하는 단계.
13. The functional food according to claim 12, wherein the cambium-derived cambium-derived stem cells are separated by a separation method comprising the steps of:
(a) obtaining a cambium-containing tissue from ginkgo;
(b) culturing the obtained cambium-containing tissue in a medium; And
(c) obtaining cambium-derived stem cells from cambium separated from calli of said cultured tissue.
13. The method according to claim 12, wherein the culture comprises culturing the stem cells in a medium containing 3-5% (g / L) raw sugar or sugar; And methyl jasmonate. The functional food according to claim 1 or 2,
13. The functional food according to claim 12, wherein the extract is extracted using a solvent selected from the group consisting of distilled water, alcohol, acetone, dimethyl sulfoxide (DMSO), and a mixed solvent thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100119347A KR101765599B1 (en) | 2010-11-29 | 2010-11-29 | Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100119347A KR101765599B1 (en) | 2010-11-29 | 2010-11-29 | Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120057828A KR20120057828A (en) | 2012-06-07 |
KR101765599B1 true KR101765599B1 (en) | 2017-08-08 |
Family
ID=46609555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100119347A KR101765599B1 (en) | 2010-11-29 | 2010-11-29 | Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101765599B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116589606B (en) * | 2022-12-01 | 2024-05-28 | 中国药科大学 | Butyrylated yeast glucan as well as preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100723609B1 (en) | 2006-04-28 | 2007-06-04 | 주식회사 유유 | Ginkgo biloba leave extract having novel composition useful for prevention or treatment of alzheimer's disease and parkinson's disease, and extracting and purifying method thereof |
-
2010
- 2010-11-29 KR KR1020100119347A patent/KR101765599B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100723609B1 (en) | 2006-04-28 | 2007-06-04 | 주식회사 유유 | Ginkgo biloba leave extract having novel composition useful for prevention or treatment of alzheimer's disease and parkinson's disease, and extracting and purifying method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20120057828A (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Okwu et al. | Phytochemical composition and biological activities of Uvaria chamae and Clerodendoron splendens | |
KR101141166B1 (en) | Plant Stem Cell Derived from Cambium of Family Gingkoaceae and Method of Isolating the Same | |
ES2303512T3 (en) | ECHINACEA SUPPLEMENT AND MANUFACTURING METHOD. | |
US8628965B2 (en) | Composition of cultured grape cells | |
KR101147861B1 (en) | Composition for Preventing or Treating Acquired Immunodeficiency Syndrom Comprising Plant Stem Cell Line Derived from Cambium of Panax ginseng Including Wild Ginseng or Ginseng | |
WO2006051334A1 (en) | Plant cells and uses thereof | |
US9603885B2 (en) | Picrorhiza extract for prevention, elimination and treatment of infection diseases | |
Kanoma et al. | Qualitative and quantitative phytochemical screening of cola nuts (Cola nitida and Cola acuminata) | |
KR101765599B1 (en) | Anti-inflammatory Composition Comprising Plant Stem Cell Derived from Cambium of Family Ginkgoaceae | |
KR20170079749A (en) | Composition comprising an extract of Artemisia lvandulaefolial or Aster scaberl for treating insect disease | |
KR101317668B1 (en) | Pharmaceutical composition for treating and preventing arthritis comprising stauntonia hexaphylla leaf extract | |
Kumar et al. | In vitro morphogenesis of Aloe vera: the “medicinal wonder” plant | |
Govindarajan et al. | Phytochemical and therapeutic evaluation of leaf and in vitro derived callus and shoot of Solanum trilobatum | |
KR20080101344A (en) | Composition for the anti-inflammatory and analgesia comprising tannin-contained kalopanacis cortex extract | |
KR102165239B1 (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract | |
US20090275105A1 (en) | Process for the production of bromelain by means of substances that induce proteins in pineapple plants | |
KR100912735B1 (en) | Composition for the anti-inflammatory and analgesia comprising rutin-contained Sophora japonica extract | |
KR20160130624A (en) | A Pharmaceutical Composition Comprising Extract or Fraction of Salvia plebeia R. Br. for Preventing or Treating Gout | |
Bindu et al. | In vitro propagation of Pueraria tuberosa (Roxb. ex Willd.) DC | |
RU2236244C2 (en) | Immunotropic preparation "vitulin b" | |
KR100646078B1 (en) | Composition containing Ligustrum japonicum extract for prevention and treatment of neurodegenerative disease | |
KR100880712B1 (en) | Pharmaceutical composition for the anti-inflammatory and analgesia comprising tannin-contained extract from Actinidia polygama fruit | |
Kumar et al. | Antibacterial, Antidiabetic and Anticancer Activities of Natural Products of Some Medicinal Plants of Muzaffarpur District | |
JPH0466536A (en) | Antiviral substance and production thereof | |
AU2003244612B2 (en) | Use of plant tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |